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To determine volume, clinical characteristics, appropriateness of, and time-to-access 
carotid artery ultrasound (U/S) testing; and, to describe requirements for an electronic 
ordering solution.
Background
Carotid artery disease is a cause of stroke and transient ischemic attack (TIA). Carotid 
imaging is urgently required in patients with recent neurological symptoms arising 
from the carotid territory to diagnose critical stenosis and eligibility for carotid 
revascularization.
Methods
Utilization of carotid artery U/S testing in adults at the vascular laboratory operated by 
Eastern Health was evaluated. In phase I, data from 2007-19 were analyzed for incidence 
of testing, clinical characteristics of the tested cohort, appropriateness of testing, and 
time-to-access testing. Phase II interventions were aimed at improving access to testing. 
Phase III involved documentation of learnings into requirements for an electronic test-
ordering solution.
Results
22,167 adults were tested. 35% of testing was for appropriate reasons and 29% resulted 
in a diagnosis of critical carotid disease. Prediction of clinically significant stenosis using 
referral data was poor. At baseline, time-to-access testing was prolonged and 85% of incoming 
requisitions were defective (unable to triage). Following interventions, mean time-to-access 
was reduced for highest priority referrals and referral quality improved to a 23% defect rate.
iii
Conclusions
Although improved access to testing and referral quality were observed with 
enhancements to the ordering requisition, streamlined triage and scheduling processes, 
and knowledge translation initiatives, time-to-access was not optimal in patients with 
recent neurological events. Learnings informed the design of an electronic ordering 
solution aimed at improving access for highest priority patients.
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CHAPTER 1 – INTRODUCTION
Stroke places enormous burden on people and the healthcare system. Worldwide, 
stroke is a leading cause of mortality and the number one cause of adult disability. In 
Canada, stroke is the third leading cause of death. Approximately 62,000 people are 
treated in Canadian hospitals for stroke each year, at an annual cost of more than $3.6 
billion (Heart and Stroke Foundation, 2018). Amplifying stroke’s direct incidence, it is 
estimated that for every symptomatic stroke there are nine covert, or undetected, strokes 
resulting in some degree of vascular cognitive impairment (Heart and Stroke Foundation, 
2018).
Causes of stroke. Stroke occurs when blood stops flowing to any part of the brain, 
damaging brain cells. There are two types, hemorrhagic and ischemic. Hemorrhagic 
stroke occurs when a weakened artery in the brain ruptures, interrupting blood 
flow within its territory, allowing bleeding and compression to surrounding tissues. 
Hemorrhagic stroke is less common at 13% of all cases, often resulting from aneurysms 
and arteriovenous malformations (Heart and Stroke Foundation, 2018). In contrast, 
ischemic stroke occurs when a vessel supplying blood to the brain is obstructed, most 
often by atherosclerotic plaque build-up. The blood clot, or thrombus, may develop 
within the brain (cerebral thrombosis), or travel to the brain from another site such 
as the heart or carotid vessels (cerebral embolism) (Heart and Stroke Foundation, 
2018). Ischemic stroke is much more common, making up 87% of all events. In both 
hemorrhagic and ischemic stroke, the person’s outcome depends upon which area of the 
brain was damaged and the degree of injury to the tissues (Heart and Stroke Foundation, 
2018).
Risk factors. An individual’s risk of stroke is increased by modifiable lifestyle factors 
such as unhealthy diet, physical inactivity, obesity, smoking, drug and alcohol abuse, 
and stress. These may contribute to the development of health conditions that also 
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increase stroke risk such as high blood pressure, high serum cholesterol, diabetes, atrial 
fibrillation, and vascular cognitive impairment. Non-modifiable factors including South 
Asian, African, and Indigenous heritage, age, and family history of cardiovascular disease 
also increase a person’s risk of stroke.
Burden of disease. Each year in Newfoundland and Labrador, approximately 1500 
people suffer stroke, and incur upwards of $235 million in direct and indirect stroke-
related expenses (Newfoundland and Labrador Centre for Health Information, 2019; 
Newfoundland and Labrador Integrated Stroke Strategy, 2013). This burden will increase 
with projected growth in risk factor prevalence and continued demographic shift towards 
‘graying’ of the population. From both a financial and human perspective, stroke 
continues to exact its price for years after the initial event, as people cope with medical 
complications, mental health issues, changes in independence, and other impacts of living 
with stroke.
Secondary stroke. In an estimated 16–30% of strokes, people suffer stroke ‘secondary’ 
to a warning event (Kocaman, 2015; Hong, 2011). These heralding events are known 
as transient ischemic attacks (TIA), or mini-strokes, and are defined as, ‘temporary 
focal loss of cerebral or ocular function attributed to ischemic vascular disease lasting 
less than 24 hours’ (Easton, 2009). TIAs indicate temporary compromise to brain 
tissue that is salvageable, but at high risk of future infarction. The mechanism of injury 
most commonly linked to TIA is large artery atherosclerosis; plaques accumulating in 
large arteries (particularly the aortic arch, carotids, and intracranial vessels) become 
unstable, allowing pieces to separate and move into the cerebral circulation (Tsivgoulis, 
2018). Mobile plaques temporarily disrupt perfusion, causing transient ischemia, or 
TIA. Permanent injury, (stroke) occurs when plaques occlude vessels that perfuse large 
territories of brain tissue (Bose, 2017). In keeping with this etiology, strokes occurring 
after TIA tend to be catastrophic i.e., severely disabling or fatal, and tend to occur within 
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48 hours of the warning event (Bose, 2017). The etiology of secondary stroke explains 
the critical importance of urgent recognition and intervention in the event of TIA. 
Prevention of secondary strokes. There have been many advances in stroke care, 
but prevention remains, without question, the pinnacle of ‘outcomes.’ Far superior to 
managing a completed stroke with sophisticated drugs, procedures, and rehabilitation, is 
identifying a person at risk and intervening to prevent the event. As Hong et al. (2011) 
conclude, the last 50 years of clinical trials have brought preventative therapies of proven 
efficacy into clinical practice including anti-hypertensive, anti-platelet, and anti-coagulant 
medications, and re-vascularization procedures such as carotid endarterectomy. Research, 
including several landmark clinical trials (EXPRESS, SOS-TIA), has demonstrated that 
identification and risk stratification of TIA, followed rapidly by effective medical/surgical 
management, can prevent 80% of secondary strokes (Giles, 2007; Lavallee, 2007). That 
is, by recognizing the forewarning provided by TIA, patients, clinicians, and the health 
care system can take preventative measures to save many lives and prevent enormous 
disability caused by secondary stroke. Critical to the secondary stroke prevention process 
is that patients with neurological symptoms arising from the carotid artery territory access 
carotid artery testing within 24 hours, if symptoms have occurred within the previous 48 
hours, and within 14 days if symptoms have occurred within more than 48 hours. This 
allows the presence of critical carotid disease to be diagnosed and patient eligibility for 
carotid artery revascularization to be determined. 
Carotid revascularization. Carotid endarterectomy is the revascularization procedure 
recommended as soon as possible and within 14 days of the onset of carotid territory 
ischemia caused by atherosclerotic stenosis of the carotid artery (Gocan et al., 2016; 
Heart and Stroke Foundation, 2018). Carotid endarterectomy involves opening the 
carotid artery at the site of occlusion, removing the plaque, and repairing the artery with 
a graft from vein elsewhere in the body, or a woven patch. When performed within target 
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timeframes (14 days of symptom onset), by a surgeon and/or centre that routinely audits 
perioperative stroke and death rates, carotid endarterectomy substantially reduces the 
risk of secondary stroke in patients with ipsilateral carotid stenosis of 70–99% (severe 
stenosis) and appropriately selected patients with 50–69 % (moderate stenosis) (Heart and 
Stroke Foundation, 2018). In the severe group, carotid endarterectomy has been shown to 
reduce the 2-year risk of stroke or death by more than 80 %, from greater than 1 in 4, to 
less than 1 in 10; and, in the moderate group, Carotid endarterectomy reduces the 5-year 
risk of stroke or death from greater than 1 in 4 to less than 1 in 7 (Barnett et al., 1991; 
National Institute of Neurological Disorders and Stroke, 2020; Rerkasem et al., 2017).
Care gap. Despite well-established evidence-based recommendations to guide secondary 
stroke prevention, an 80% level of risk reduction for secondary stroke has been difficult to 
achieve in clinical practice. While improved secondary prevention outcomes are becoming 
more evident, epidemiological data indicates secondary stroke events remain common 
(Gocan et al., 2016). In some cases, upwards of one in four patients with completed stroke 
have had a warning event (Hong 2011; Kocaman 2015). Rothwell et al., (2007) found of 
2416 patients presenting with ischemic stroke, 23% had a warning event. Data from the 
Quality of Stroke Care in Canada Report (2011) shows national secondary stroke rates at 
approximately 12% and region-specific data from the same study shows the incidence of 
secondary stroke in Newfoundland and Labrador to be much higher, at 19.8%. 
Examining these data from a prevention perspective, if approximately 800,000 
people have a stroke annually, as is the case in the United States, approximately 200,000 
are recurrent, i.e., a TIA had provided clear warning that a stroke was imminent, and 
80% of these or 160 000 strokes, could be prevented. In Canada, effective secondary 
prevention could reduce the annual incidence of stroke by 16,250, and in Newfoundland 
and Labrador (NL), high quality secondary prevention could translate to approximately 
400 fewer strokes each year. In NL, the median acute care length of stay for stroke 
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is 8 days, thus 400 fewer strokes could reduce the burden on acute care resources by 
3200 acute care bed days annually (Newfoundland and Labrador Centre for Health 
Information, 2019).
The discrepancy between the secondary prevention potential reported in academic 
research and the outcomes seen in clinical settings raises important considerations 
regarding the translation of evidence into practice. Bringing health research from bench 
to bedside requires an appreciation for the practicalities of health system substructure 
that may hinder the delivery of optimal care. In secondary stroke prevention, there 
is widespread acknowledgement of the gap between evidence and practice. Given 
the particularly high incidence of secondary stroke in NL, there is justification for an 
examination of its clinical components to identify opportunities for improving outcomes. 
This epidemiological evaluation examines local clinical processes underpinning 
secondary stroke prevention, specifically: access to carotid imaging. 
Patients presenting acutely with symptoms of carotid artery territory occlusion 
require testing, or imaging, of the carotid arteries to evaluate the presence and degree of 
carotid stenosis. Carotid artery imaging is frequently obtained using Doppler U/S. In this 
non-invasive test, sound waves are used to visualize the flow of blood through the arteries 
and measure its velocity. Imaging of the carotid arteries can also be obtained using 
computed tomography angiography (CTA) or magnetic resonance angiography, where 
digital images are created using radio and/or magnetic waves. These methods of imaging 
the carotid arteries are used to determine eligibility for surgical revascularization using 
carotid endarterectomy to prevent stroke. Carotid endarterectomy is recommended within 
48hrs of symptom onset in eligible patients, therefore rapid access to carotid imaging is 
critical to effective secondary stroke prevention.
Local context. The primary site for carotid artery testing in Eastern Health (a health 
authority serving a rural and urban population of about 250,000 residents) is at the 
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vascular laboratory at St. Clare’s Hospital, using ultrasound. Carotid imaging may also be 
carried out at other facilities within Eastern Health and elsewhere in the province using 
ultrasound, CTA, or magnetic resonance angiography. The care process being evaluated is 
outlined in Figure 1.
Figure 1. The process for carotid artery imaging following the acute onset of neurological symptoms 
suggestive of carotid artery occlusion. Original figure.
This thesis is written in traditional style with chapters corresponding to the components 
of the project. The research questions addressed were:
1. What are the volume, and clinical and demographic characteristics of patients referred 
for carotid U/S from 2007–2019 at St. Clare’s Hospital, Eastern Health Authority, NL; 
and, how appropriate was the referral?
2. What was the time-to-access carotid U/S (hours, days) in patients referred for testing 
at baseline (March-June, 2015) and after process improvement took place (July 2015-
June, 2017)?
3. Could an electronic test-ordering solution be designed to improve access to U/S in 
symptomatic patients arising from the learnings of phases I and II and input from 
stakeholders?
Neurological symptoms arising from cerebral 
territory perfused by the carotid artery
Carotid artery U/S to identify presence, extent, 
and location of carotid artery occlusion
Symptom onset within 48 hours; 
imaging within 24 hours
Symptom onset more than 48 hours; 
imaging within 48 hours-14 days
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CHAPTER 2 – LITERATURE REVIEW
The following literature review examined clinical and administrative principles and 
processes underpinning secondary stroke prevention. Consequently, it reviewed 
recognition and reaction of the public to symptoms of a TIA; diagnosis and management 
of a TIA; access to carotid artery imaging; imaging of extra-cranial vessels; carotid 
endarterectomy; coordination of care; referral to dedicated secondary prevention clinics; 
clinical handover and paper processes; and, shift to electronic tools.
2.1 Search Strategy
Publications were located through searches of PubMed, CINAHL, EMBASE, and 
Google Scholar. A combination of the terms: secondary stroke, transient isch(a)emic 
attack (TIA), minor isch(a)emic stroke, extra-cranial, imaging, carotid, access, testing, 
and prevention (Figure 2.) yielded 743 articles. Most papers dealt with the broad topic 
of secondary stroke prevention. Additional search terms were applied including carotid 
imaging pathway, efficiency, appropriateness, clinical practice guidelines, electronic, 
decision support, electronic order, electronic referral, barriers, facilitators, delay, errors, 
referral quality, and defects. Filters were applied, limiting results from 2005 to 2019. A 
Cochrane Database search was carried out utilizing the same list of terms. The final yield 
was 53 articles, 9 of direct relevance. All 53 were reviewed and reference lists explored 
for additional publications.
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Table 1. Inclusion/Exclusion Criteria used in Search of Literature 2005–2019 for Articles Relevant to 
Improving Access to Carotid Imaging 
Inclusion Criteria Exclusion Criteria
Experimental design: randomized control trials (RCT) preferred but given the 
paucity of evidence, all experimental study designs were reviewed.
Peer-reviewed publications.
Articles written in English or English translation.







One particular author, Dr. Annemarei Ranta of New Zealand, has been actively 
working in the area of electronic decision support in access to carotid artery imaging in 
secondary stroke prevention, and is the only researcher identified with multiple relevant 
publications. She was contacted in the event she was aware of other research or gray 
literature pertinent to this review. Dr. Ranta responded personally but was not able 
to recommend any further literature. She confirmed a paucity of research on process 
improvement in acute secondary stroke prevention, specifically use of electronic decision 
support pathways and/or electronic test ordering of carotid artery investigation.
Figure 2. Diagram of search strategy utilized to identify peer-reviewed papers relevant to the topic of 
access to carotid imaging in secondary stroke prevention.
Cochrane search: 
0 new articles
PudMed, CINAHL, EMBASE, and 
Google Scholar: 743 articles
119 articles
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2.2 Critical Appraisal Process
Each article was assessed for methodological rigor and relevance to the research. 
Inclusion criteria are presented in Table 1. The objective was to determine if the evidence 
presented was strong and generalizable based on criteria employed by the Canadian 
Stroke Best Practices Writing Groups, and the Centre for Evidence Based Medicine 
(Heart and Stroke Foundation, 2018; Howick, 2011). Elements assessed included: 
research design, sample characteristics and recruitment methods, follow-up, data 
collection/analysis, sources of bias, and confounders. Key themes identified through the 
literature review relevant to accessing extra-cranial imaging are discussed below.
2.3 The Secondary Stroke Prevention Process
Effective acute secondary stroke prevention encompasses a series of activities and 
responses by patients, practitioners, and the health care system. Broadly, these include 
recognition and reaction to indicators of risk and warning symptoms; initiation of 
investigations and medical management; analysis of findings; and, in eligible patients, 
surgical intervention through carotid endarterectomy (Bose et al., 2017).
Extra-cranial imaging is carried out to identify patients who may benefit from 
carotid endarterectomy to prevent stroke (Figure. 3). Carotid endarterectomy is a surgical 
revascularization procedure performed to enable blood flow to the brain via the carotid 
arteries. Carotid endarterectomy is effective for symptomatic patients with moderate to 
high-grade ipsilateral stenosis, but its effectiveness is highly time-dependent. The number 
needed to treat (NNT) is 5 among those undergoing carotid endarterectomy within 2 
weeks of symptoms, compared with 125 among those undergoing the procedure after 12 
weeks (Gocan et al., 2016). These diminishing returns over time explain why warning 
events suggestive of carotid territory ischemia are a medical emergency, necessitating 
swift access to investigation and treatment. 
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Figure 3. Key clinical milestones in the acute secondary stroke prevention process. (QSCIC Key Indicator # 
36). Original figure.
Important components of the clinical timeline from symptom onset-to-carotid 
endarterectomy are symptom onset-to-presentation; presentation-to-carotid imaging; 
and, carotid imaging-to-carotid endarterectomy. According to the Quality of Stroke Care 
in Canada (QSCIC) (2011), these constituent times comprise an overall performance 
indicator of, ‘time from symptom onset to carotid revascularization’ (QSCIC Key 
Indicator # 36). Figure 3 highlights key steps in the process of acute secondary 
prevention. Reduced efficiency anywhere along this process may result in a missed 
opportunity for effective secondary stroke prevention.
2.4 Public Recognition and Reaction to TIA
The first steps in successful secondary stroke prevention encompass recognition of 
neurological symptoms arising from the carotid artery, and appropriate reaction by the 
individual. Despite widespread and coordinated public awareness efforts, recognition and 
reaction to the signs and symptoms of stroke by the general public is sub-optimal (Duque 
et al., 2015). A recent Canadian survey revealed 50% or fewer respondents could name 
two signs of stroke, (Heart and Stroke Foundation of Canada, 2018). Similar results from 
other jurisdictions confirm these findings (Gocan et al., 2016; Groschel et al., 2011). 
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In response to this issue, many jurisdictions have focused on public awareness 
campaigns designed to improve stroke symptom recognition and reaction. In North 
America, the acronym ‘FAST’ is used (Figure 4). FAST reminds people that acute 
onset of symptoms involving the Face, Arm, and Speech indicate it is Time to activate 
emergency medical services. FAST was recently adopted by the Heart and Stroke 
Foundation (HSF) of Canada as a replacement for their pre-existing approach to public 
awareness of stroke signs and symptoms. The new, four-item FAST strategy is also used 
by HSF counterparts in the United States, Europe, and other areas of the world, enabling 
a coordinated public awareness approach across jurisdictions. 
Figure 4. Example of Heart and Stroke Foundation of Canada’s FAST resources used to increase public 
recognition of stroke symptoms (Heart and Stroke Canada, 2014). Used with permission of Heart and 
Stroke Foundation of Canada.
Evaluation of the effectiveness of ‘FAST’ indicates individuals exposed to ‘FAST’ 
multimedia campaigns become better able to recognize the signs and symptoms of stroke, 
and show improved knowledge of appropriate action i.e., call 911 (Environics, 2009; 
Heart and Stroke Foundation of Canada, 2018; Jurkowski et al., 2008; Bray et al., 2013). 
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In light of the known limitations in awareness and appropriate reaction to the 
signs and symptoms of stroke by the public, it is not surprising that epidemiological 
data confirm people experiencing hyperacute stroke and/or TIA delay seeking treatment 
(Gocan et al., 2016; Groschel et al., 2011). Many go first to their general practitioner (GP), 
(Bose et al., 2017; Chandratheva, 2010). Even when symptom onset is outside traditional 
general practitioner office hours, i.e., when onset is in the evening or on the weekend, 
many people wait for their General practitioner to open and provide an appointment rather 
than go directly to an emergency department (ED), (Bose et al., 2017; Bray et al., 2013; 
Chandratheva, 2010; Fairhead et al., 2005). This creates an immediate delay. 
Intensifying the problem, general practitioners are known to have poor accuracy 
in diagnosing TIA, (Bose et al., 2017; Massengo et al., 2013; Ranta 2013). Literature 
from multiple countries confirms this pervasive issue, also showing emergency room 
physicians (ERPs) and neurologists are often poor identifiers of TIA, (Bose et al., 2017; 
Bray et al., 2013; Chandratheva, 2010; Fairhead et al., 2005; Jeerakathil et al., 2014; 
Massengo et al., 2013; Ranta 2013).
2.5 Diagnosis and management of TIA
While recognition of stroke symptoms, and knowledge of appropriate reaction are 
necessary components of secondary stroke prevention, they do not guarantee an effective 
response at first contact with the health system. Upon presentation, the cornerstones 
of evidence-informed acute secondary prevention are rapid identification and risk 
stratification, investigation, initiation of medical treatment, and surgical revascularization, 
where appropriate (summarized in Figure 3). 
A TIA is defined as “temporary focal loss of cerebral or ocular function attributed 
to ischemic vascular disease less than 24 hours” (Easton 2009). The temporary nature of 
the symptoms indicate that urgent imaging is needed to diagnose critical coronary artery 
Page 13 | Chapter 2
disease, rather than provision of tissue plasminogen activator (tPA) or other interventions 
to treat an established stroke.
Multiple examples of best practice recommendations for secondary stroke 
prevention are available to support care, including the current Canadian guidelines (Heart 
and Stroke Foundation, 2018). These resources provide trusted guidance on accurate 
identification and management of patients, but despite efforts to encourage uptake, the 
literature confirms non-adherent practice is a pervasive problem (Bose et al., 2017; 
Brownlee et al., 2014; Jarhult et al., 2017; Raposo et al, 2018).
Beyond initial identification, research shows primary providers and Emergency 
room physicianss have limited knowledge of up-to-date guidelines for secondary 
prevention, and may not follow best practices (Raposo et al, 2018; Sales et al., 2015). 
Amplifying these issues, within the health system the use of standardized stroke 
management protocols is inconsistent, and the information exchange processes used to 
coordinate care across sectors are often not optimized for efficiency and effectiveness. 
For example, standardized hyperacute stroke/TIA protocols (paper-based or electronic) 
are inconsistently deployed across jurisdictions. In the province of NL, efforts are 
underway to implement standardized operating procedures for hyperacute stroke 
(Code Stroke), but a TIA protocol has not yet been introduced. Figure 5 illustrates an 
evidence-based resource for management of TIA developed to support care providers in 
Newfoundland and Labrador.
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Figure 5. CODE TIA Pocket Card produced by Quality of Care NL, adapted from Canadian best practice 
recommendations for secondary stroke prevention (Quality of Care NL, 2018). This resource was 
developed to support health care providers with risk stratification and appropriate management of 
individuals presenting with TIA. Used with permission of Quality of Care NL. 
2.6 Imaging of Extra-Cranial Vessels 
Where there is high clinical suspicion of TIA or stroke arising from brain territory 
perfused by the carotid arteries, imaging is urgently required. Imaging of extra-cranial 
vessels may be obtained using several methods, however CTA is the recommended 
modality (Heart and Stroke Foundation, 2019; Wein et al., 2017). Aside from providing 
exceptional image quality, CTA is widely available, even in remote areas (Kramer et al., 
2015). Doppler U/S is also recognized as an acceptable modality and MRA, in some 
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cases (Heart and Stroke Foundation, 2019). These tend to be less accessible and in the 
case of Doppler U/S, testing is more time-consuming, and the accuracy of findings is 
highly technician-dependent (Birmpili et al., 2018; Kramer et al., 2015). Thus, to ensure 
inter/intra-rater reliability with the use of Doppler U/S, a consistent quality assurance 
process is required (Birmpili et al., 2018). 
In Newfoundland and Labrador, carotid Doppler U/S is widely utilized for carotid 
imaging. The tertiary Vascular Surgery program based in St. John’s operates an accredited 
Vascular Laboratory. The four vascular surgeons carrying out carotid endarterectomy in 
this province rely heavily upon carotid Doppler U/S to evaluate degree of stenosis in the 
determination of surgical eligibility for carotid revascularization. For this reason, time-
to-access carotid imaging at the Vascular Lab is of critical importance to patients who 
undergo carotid endarterectomy in Newfoundland and Labrador. In some cases, patients 
referred for carotid endarterectomy have imaging completed at regional health authority 
sites other than the Vascular Lab. If the degree of stenosis has been evaluated elsewhere 
using CTA or magnetic resonance angiography, patients proceed directly to surgery. If, 
however, the imaging has been obtained via U/S at another (non-accredited) facility, the 
testing is repeated at the Vascular Lab.
2.6.1 Carotid Endarterectomy
Carotid endarterectomy has been shown to be highly beneficial in preventing stroke 
recurrence in patients who have experienced a minor stroke or TIA when there is 
high-grade/severe stenosis (70–99% narrowing) of the carotid artery supplying the 
affected brain tissue; and, modestly effective when there is moderate stenosis (50–69% 
narrowing) (Heart and Stroke Foundation, 2018). In neurologically stable individuals, 
carotid endarterectomy was most beneficial within 2 weeks of symptom onset and 
benefits decreased rapidly with increasing delay (Barnett et al., 1991; Rothwell et al., 
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2007). Several large trials have been conducted comparing carotid endarterectomy for 
symptomatic stenosis with best medical treatment, including a 2017 Cochrane review 
(Rothwell et al., 2007; Rerkasem et al., 2017). The risk of stroke or operative death at 
5-years in patients with severe stenosis (70–99%) was significantly reduced in patients 
in the carotid endarterectomy group (relative risk (RR) =0.53, 0.42–0.67, p<0.0001, 
NNT=6) with an associated absolute risk reduction of 16.0% (Rothwell et al., 2007; 
Rerkasem et al., 2017). For patients with moderate stenosis (50–69%), the risk was also 
reduced (RR=0.77, 0.63–0.94, p=0.001, NNT=22) and for patients with mild stenosis 
(<50%), there was no benefit of carotid endarterectomy. Perioperative death or stroke 
incidence was 7.0% (95% confidence interval (CI) 6.2 to 8.0) and the greatest benefits 
of carotid endarterectomy were found in men, patients aged 75 years or over, and those 
randomized to treatment within two weeks of symptom onset (Rothwell et al., 2007; 
Rerkasem et al., 2017). 
Although carotid endarterectomy has been shown to significantly reduce stroke 
risk, its effectiveness is highly time-dependent, with a number needed to treat of five 
among those who undergo surgery within 2 weeks, compared with a number needed  
to treat of 125 among those receiving surgery after 12 weeks (Gocan et al., 2016).  
For optimal stroke prevention, international best practice guidelines recommend carotid 
endarterectomy intervention as soon as possible for appropriate candidates, with a  
target time of intervention in less than 2 weeks of symptom onset (Gocan et al., 2016).  
In keeping with these findings, the Canadian Stroke Best Practice Recommendation for 
management of patients with recent TIA or non-disabling stroke and 50–99% stenosis is 
immediate evaluation by an individual with stroke expertise and extra-cranial imaging to 
determine the presence, extent, and location of stenosis; and, eligible patients should be 
offered carotid endarterectomy as soon as possible after symptom onset and within  
14 days (Heart and Stroke Foundation, 2018).
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2.6.2 Coordination of Care
A consideration in secondary stroke prevention is consistency in triage/management 
principles utilized by individual sectors of care such as EDs, general practitioners, 
Diagnostic Imaging (DI), and vascular surgery. A mismatch in response and triage 
principles between interdependent entities within secondary stroke prevention processes 
may result in disorganized care that falls short of performance targets. This concept is 
illustrated in the 2018 work published by Mofidi et al., showing improved outcomes for 
surgical candidates with symptomatic carotid stenosis when an integrated care pathway 
was utilized in comparison to usual care.
To demonstrate the above with an example: patients may present to an ED with 
acute onset of symptoms suggestive of carotid territory ischemia. ED and DI services are 
often separate, both organizationally and physically. A classic set of local events might 
entail a requisition being submitted to DI by the ED, requesting brain and extra-cranial 
(carotid) imaging. If the ED is treating the patient with a high index of suspicion for acute 
ischemic event and moving rapidly towards determining eligibility for time-dependent 
therapy such as thrombolysis or carotid endarterectomy, they may incorrectly assume DI 
is following the same approach (or vice versa). Simultaneously, DI’s protocol may be to 
complete brain imaging at the time of presentation or to schedule extra-cranial imaging 
for ‘next business day’.
In a more efficient scenario, a standardized, electronic, acute stroke and TIA 
protocol would ensure patients en route or arriving to ED with suspected acute carotid 
territory ischemia are made immediately known to DI (Jarhult et al., 2017). This enables 
DI to enact a ‘next on table’ protocol that expedites unenhanced CT head and CTA of 
extra-cranial vessels during the same scan, if clinically warranted and safe. Without 
such a coordinated approach, the extra-cranial vessels may not be investigated rapidly, 
or at all. If not specifically ordered at the time of initial presentation, CTA of carotid 
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vessels may require separate paperwork and a subsequent appointment. This is despite 
a clear opportunity to adhere to a best practice protocol and complete testing in one 
imaging episode at the time of initial presentation. Patients not affiliated with a general 
practitioner are at even greater risk that imaging of extra-cranial vessels may be delayed 
or missed (Raposo et al., 2018; Sales et al., 2015).
The potential impacts of mismatched service delivery models include delay 
and uncoordinated care. An optimized scenario would see services integrated so that 
each sector performs their part with unambiguous communication and clarity of roles 
and responsibilities, in the shortest period of time. The scenario described above 
is not uncommon across provincial jurisdictions, and may help explain why even 
comprehensive stroke centres often fail to achieve rapid access to carotid endarterectomy 
(Jarhult et al., 2017; Blacquiere et al., 2013).
Given known deficiencies in systemic and individual clinician ability to execute 
effective secondary prevention, it is not surprising that patients, even those presenting 
promptly, may experience ineffective management. Patients often leave the initial 
point of care without appropriate medications (anti-thrombotics); they may not receive 
brain imaging immediately; and, they frequently do not access rapid imaging of carotid 
vessels or carotid endarterectomy within recommended timeframes (Bose et al., 2017; 
Brownlee et al., 2014; Jarhult et al., 2017; Raposo et al., 2018; Sales et al., 2015). 
Canadian and Newfoundland and Labrador data confirm these issues exist locally. The 
Quality of Stroke Care in Canada 2011 report showed only 22% of patients diagnosed 
with ischemic stroke received brain imaging within 1 hour of emergency arrival, and 
only 72% of people had brain imaging within 24 hours (Heart and Stroke Foundation of 
Canada, 2011). Similar concerns persist at the provincial level. Data from the 2017/18 
fiscal period indicate 84.7% of admitted patients with confirmed stroke in this province 
had brain imaging within 24 hours, and only 69.6% were discharged on antithrombotic 
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therapy (Newfoundland and Labrador Centre for Health Information, 2019).
Best practices for secondary prevention recommend patients receive advice on 
lifestyle modification as well as educational resources, appropriate monitoring, and 
streamlined transitions of care (Wein et al., 2017). This includes support for smoking 
cessation, weight loss/dietary changes, and physical activity. Studies show primary 
providers, emergency room physicians, and neurologists often neglect these topics, thus 
many patients at risk do not receive appropriate follow-up, monitoring, and supported 
risk factor modification (Ranta et al., 2013).
2.7 Referral to Dedicated Secondary Prevention Clinics 
The model of practice from the two landmark studies achieving 70–80% risk reduction 
in secondary stroke entails 24-hour/7-day access to secondary stroke prevention clinics 
(Rothwell et al., 2007; Lavallee et al., 2007). Dedicated stroke prevention clinics 
typically use standardized protocols for rapid intake and optimization of medical therapy 
to coordinate access to required investigations and interventions, and to arrange ongoing 
follow-up (Gocan et al., 2016; Jarhult et al., 2017; Jeerakathil et al., 2014).
Authentic duplication of the academically-described rapid access model is 
problematic. In many jurisdictions, specialist-driven models are infeasible, as specialist 
care is typically concentrated in urban areas. Canadian epidemiological data shows the 
initiation of secondary prevention frequently falls to general practitioners or emergency 
room physicians, and proceeds in a fragmented course across geographic and health 
sectoral boundaries (Heart and Stroke Foundation, 2011). The 2011 Quality of Stroke 
Care in Canada report shows over half of Canadian patients with stroke are managed by 
general practitioners, including in Newfoundland and Labrador. 
This province provides an example of the infeasibility of replicating the dedicated 
models of secondary stroke prevention utilized in research settings. With a population of 
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approximately 500,000 people scattered heterogeneously over a challenging landmass 
about twice the size of the United Kingdom, rapid access to basic care can be a challenge. 
As of 2018, one secondary stroke prevention clinic, primarily serving the most densely 
populated area of the province, was resourced by a single neurologist, without the 
benefit of Telehealth. Access to the clinic is limited to Monday-Friday, business hours, 
and is restricted by the neurologist’s other duties. The sole neurologist coordinates all 
investigations and follow-up initiated from the clinic. 
Some jurisdictions with higher population density and greater access to specialty 
services may operate rapid access clinics without genuinely reproducing the round-the-
clock model employed by the EXPRESS or SOS-TIA trials (Giles, 2007; Lavallee, 2007). 
Paradoxically, rapid access clinics operating Monday-Friday, business hours or less, 
amount to ‘partial rapid access’ and may actually contribute to delayed care. Blacquiere 
et al., 2013, describe a rapid access clinic that was operational 2–3 days/week. In such 
designs, patients presenting outside operating hours do not have access to optimal care. 
Compounding the problem, after-hours patients influence the care of people presenting 
during operating hours because the backlog they create must be managed before new 
patients are seen. Ironically, Blacquiere, 2013, reported participation by neurologists 
in the ‘partial rapid access’ model was a factor contributing to slower flow. Providing 
specialist care only on particular days creates a logjam effect by ‘batching’ referrals 
to be processed together. The same bottleneck effect is seen at imaging facilities and 
within surgical services, where carotid investigations and/or carotid endarterectomy are 
continuously required, but services are not operational on a 24/7 basis (Shah et al., 2013).
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2.8 Clinical Handover and Paper-Based Processes
Care transactions between sectors within the health system typically require a request/
requisition process. These may be paper and/or fax-based, verbal/telephone, occasionally 
mail, and increasingly computerized/electronic. Usually a handover of referral 
information occurs, followed by triage, appointment booking, execution of a service, 
interpretation of results, documentation of findings, and dispatch of responsibility and 
accountability for the next step in the patient’s care. As Marmor et al., (2017) discuss, 
these maneuvers take time and are at high risk for error and delay which may lead to 
patient harm. The Canadian Medical Protective Association (CMPA) describes handover 
as, ‘the transfer of responsibility and accountability for some or all aspects of care for 
a patient or group of patients, on a temporary or permanent basis,’ (Canadian Medical 
Protective Association, 2019). The large body of literature on safety in clinical handover 
is clear on the necessity of standardizing information transfer through the use of 
structured protocols (Eggins et al., 2015). 
The hazards associated with use of paper in health care, including clinical 
handovers, are well-documented (Canada Health Infoway, 2011). Issues such as 
illegibility, misdirection, inability to constrain responses or make fields mandatory,  
and the need for manual processing are widely acknowledged as shortcomings of 
working in paper (Menachemi et al., 2011). Paper-based transactions entail inherent risk 
of delay due to the need to physically handle requisitions for scanning, faxing, or other 
transmission between sectors. Even when paper requests are accurately and rapidly 
completed and transmitted, they must be managed by the receiving service, often 
necessitating another handover of information between administrative and clinical staff. 
These known risks raise obvious concerns about use of paper processing to execute 
clinical handovers during time-sensitive investigations and interventions in secondary 
stroke prevention.
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Paper-based processes also impair the ability to balance clinical resources. In their 
2018 systematic review, Kruse et al., highlighted the limitations of paper-based processes 
in clinical productivity and resource management (Kruse et al., 2018). As discussed by Lin 
et al., (2018), clinical sectors such as DI or Vascular Surgery must continuously balance 
their demand for services against their internal capacity to complete the work. Triage of 
incoming requests is carried out to stratify demand according to risk, providing the earliest 
slots to patients whose risk is highest (Lin et al., 2018). The ability to accurately carry 
out risk stratification depends upon access to the clinical information required for triage. 
With paper processing, the receiving service is reliant upon the referrer to legibly, and 
unambiguously, provide the required information. Without ‘critical-to-quality’ (CTQ) 
information, triage becomes inaccurate or impossible (Tripathi et al. 2017; Wahlberg et al., 
2015). This impairs the health system’s ability to routinely adjust demand against capacity, 
and to engage in informed health resource planning. The use of structured templates and 
electronic tools for both transmission of critical information and to perform triage is emerging 
(Canada Health Infoway, 2013; Wahlberg et al., 2015). In 2017, medical researchers with 
Johns Hopkins published work showing equal or more accurate triage and prediction of patient 
outcomes using an electronic triage tool (Johns Hopkins Medicine, 2017). Ranta et al., 2013, 
showed an electronic decision support tool could be used to manage new TIA referrals more 
comprehensively than General practitioners, emergency room physicians, or even neurologists. 
2.9 Shift to Electronic Tools
Electronic test-ordering solutions (eOrder) provide a prime opportunity to facilitate 
evidence-based care and to eliminate risks inherent to paper-based communication. 
To date, there is minimal evidence for the use of electronic decision support tools in 
secondary stroke prevention, and the literature confirms a persistent reliance on fax 
machines and paper processes, with both in persistent and widespread use (Bodkin, 2018; 
Page 23 | Chapter 2
Picard, 2018; Ranta et al., 2015; Toerper, 2017). 
The National Health Service (NHS) in the United Kingdom is the largest buyer 
of fax machines in the world, however recognizing the deficiencies of fax, the UK has 
recently passed legislation to phase out and prohibit future fax procurement (Bodkin, 
2018). Like the NHS, many organizations are moving towards electronic record-keeping 
and information-exchange processes, and there is a growing social movement towards 
elimination of faxing (Picard, 2018). Agencies such as Canada Health Infoway, the 
Canadian Institute of Health Information (CIHI), and the Canadian Foundation for 
Healthcare Improvement (CFHI) present public arguments for the use of digital strategies 
in health information exchange. One example is the use of the slogan, ‘#AxeTheFax’ on 
Twitter and other social media platforms (Bruce, 2019). With the shift away from paper, 
there is growing recognition that well-designed electronic tools and processes provide 
sophisticated opportunities for enhanced health care and health resource management 
(Canada Health Infoway, 2019; Menachemi et al., 2011).
2.10 Research Concept
The body of research addressing access to carotid artery imaging, to date, has focused 
largely on the relationship between delayed care and the risk of a secondary stroke, and on 
quantifying the length of delays. Less consideration has been given to dissecting why and 
where along the process delays in care exist, and the role of reliable and efficient ordering, 
triaging, and scheduling. The work outlined in this thesis evaluates local processes for 
accessing carotid artery imaging via Doppler U/S in the prevention of secondary stroke. It 
is anticipated this work will be hypothesis-generating: an examination of local processes 
will identify opportunities for improvement and inform the design of an electronic 
ordering (eOrder) solution. In future phases of research, the eOrder solution will be 
analyzed to determine impact on access to carotid artery imaging and clinical outcomes. 
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2.11 Objective and Hypothesis
As part of a suite of quality improvement initiatives targeting secondary stroke prevention 
within a regional health authority (RHA), a retrospective mixed-methods analysis of 
carotid U/S utilization was carried out with the following objectives: 
1. To analyze the utilization of carotid artery U/S imaging at a local adult testing facility, 
including:
• Volume of testing
• Clinical characteristics of the tested population
• Appropriateness of testing
• Time-to-access testing
2. To examine the effect of system enhancements supporting improved efficiency and 
appropriateness on access to testing.
3. To identify the requirements for an electronic test ordering (eOrder) solution to 
improve access to testing.
The following hypothesis was established:
In a local testing facility, processes of care for accessing carotid artery imaging using 
Doppler U/S in the management of adults presenting acutely with symptoms of carotid 
territory ischemia can be improved to enhance access for high priority patients.
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CHAPTER 3 – METHODOLOGY
This analysis was carried out with the authorization and support of Eastern Health, its 
Vascular Surgery Program, and the Centre for Health Informatics and Analytics (CHIA) 
– a sub-entity of Memorial University of Newfoundland’s Translational and Personalized 
Medicine Initiative. Ethics approval was requested of the local Health Research Ethics 
Board (HREB). The application (HREB # 2017.067) was categorized as quality 
improvement and, as such, did not require ethics approval. This is in keeping with the origin 
and intent of the work within Eastern Health as a continuous quality improvement initiative. 
Eastern Health’s quality improvement work in secondary stroke prevention is ongoing, with 
current focus on clinical implementation of an electronic ordering (eOrder) tool. 
3.1 Data
3.1.1 Interrogation of the Vascular Database (St. Clare’s Mercy Hospital Vascular 
Lab) 2007–2019. The database contains demographic and limited clinical information 
on the population of individuals investigated using carotid artery U/S at St. Clare’s 
Vascular Lab. Table 2 lists variables contained within the Vascular Database up to May 
2017. Additional data from updated software installed in the Vascular Lab from May 
2017-April 2019 were available, but did not contain the entire set of variables within 
the original 2007–2017 dataset. The additional data were analyzed for incidence and 
appropriateness.
3.1.2 Time-to-Access Information (date referral written, date received by lab, date of 
U/S, and data quality e.g., legibility) was abstracted from paper-based referral forms for 
carotid artery U/S received at St. Clare’s Vascular Lab during two discrete periods in 
2015 (March-June and August-December). Follow-up was conducted in 2016 (January-
March); and, 2017 (January-June) examining temporal information only.
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3.1.3 Qualitative Information Collection from subject matter experts including 
referrers, Vascular Lab technical and administrative staff, vascular surgeons, vascular 
program and RHA leadership, information technology staff, and patients.
Table 2. List of variables included in the electronic database pertaining to carotid artery U/S imaging at 




Sex M or F
Test ID BCSCAV (indicates ‘carotid’ vs ‘arterial’ or ‘venous’
Age at Test years
Test Date (m/d/y)
Patient Status Outpatient or Inpatient
Reason See Table 3
Peak Systolic Volume per Artery Tested RD/ICA/PSV e.g. 80 cm/s
3.2 Research Phases 
The three phases of research are largely in chronological order, however in some cases 
elements of a particular phase overlapped with the work of a phase before or after. Key 
methodological elements within each phase are summarized below, followed by an 
expanded description of the methodology for each phase.
Phase I – Utilization of Carotid Artery U/S Imaging, St. Clare’s Vascular Lab
• Analysis of the vascular database 2007–2017, including:
> Volume of testing
> Clinical characteristics of the tested population
> Appropriateness of testing
> Diagnosis of clinically significant carotid disease
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• Analysis of May 2017-April 2019 vascular data (new software):
> Volume of testing
> Appropriateness of testing
> Diagnosis of clinically significant carotid disease
Phase II – Improving Access to Carotid U/S 
• 2014 – initiation of consultation and stakeholder workshops, key informant 
interviews, observations, process documentation
• March-June 2015, baseline data collection on time-to-access carotid artery testing
• June 2015 – redesign of the requisition used within the RHA to order carotid U/S
• 2016 – Personalized audit and feedback (referrers)
• 2015–2018 – Knowledge translation initiatives (referrers, internal stakeholders). 
Includes didactic education sessions, development of an online carotid imaging 
training module, site visits, slide deck and webinar development, dissemination of a 
Code TIA pocket card 
• 2015–2018 – Public awareness campaign: social media, radio, television, newsprint, 
online, and social media dissemination of information
• Follow-up sampling of requisitions received at the Vascular Lab during 2016 
(January-March); and, 2017 (January-June) including analysis of referral quality and 
time-to-access testing
Phase III – eOrder Solution Requirements and Design
• Documentation, design, and implementation-planning of an electronic test-ordering 
solution.
> 2017/18 – eOrder requirements documentation
> 2018/19 – Co-design of eOrder software
Page 28 | Chapter 3
> 2019 – Creation of eOrder communication and training strategies
> 2019/20 (ongoing) – Deployment of eOrder
3.3 Data Preparation
Encrypted, de-identified, data files were transferred from Eastern Health to Memorial 
University of Newfoundland and stored on a secure server operated by CHIA. Industry-
standard security practices were employed to ensure data integrity and confidentiality, 
and access to the data was limited to authorized individuals.
The de-identified administrative dataset and the manually sampled data were 
formatted to an .xlsx format (Excel software). The master file of de-identified data 
included the entire population of individuals provided with carotid artery U/S at the 
Vascular Lab between 2008 and 2017; the truncated 2017–19 data from the newer lab 
software; and, the manually-collected data from baseline and follow-up sampling of 
time-to-access testing. The data were organized in a tidy fashion based on the Hadley 
Wickham definition, where each column represents a variable and each row of cells 
contains the recorded values for one individual or case corresponding to the variable 
represented by each column (Wickham, 2014).
Phase I Methods – Utilization of Carotid Artery U/S Imaging 
3.4 Indication and Appropriateness
Age was coded into five age categories: 20–50, 51–60, 61–70, 71–80, and 81–120 
years. Within the vascular database, a ‘reason for test’ was documented for each carotid 
artery U/S conducted. The ‘reason’ was selected from a dropdown menu by the vascular 
technician at the time of the test. Possible reasons selectable within the dropdown menu 
are listed in Table 3. ‘Reason for test’ was further categorized into two dichotomous 
groups: ‘indicated cerebrovascular event’ and ‘not indicated.’ Using this approach, 
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‘indicated cerebrovascular event’ encompassed stroke, TIA, and/or amaurosis fugax, a 
type of visual loss. The category ‘not indicated’ included carotid bruit, asymptomatic, 
vertigo/dizziness/syncope, and/or other.
Table 3. ‘Reason for test’ recorded by Vascular Technicians for carotid artery U/S testing requested 
between 2007–2017 at St. Clare’s Vascular Lab.






Stroke/TIA/Amaurosis Fugax Indicated 
The 2017–19 data were treated separately, as this period was transitional between 
two software systems used within the Vascular Lab. 2017–19 data came from new 
software implemented in 2017. Capture of variables in the new system is not entirely 
congruous with the 2007–17 data, resulting in discontinuity between the original 
variables and those included in the 2017–19 data. For example, ‘reason for test’ was 
not captured in the new system using identical dropdown menu options. As a result, the 
2017–19 data could not be combined with the 2007–17 data for a continuous analysis.
3.5 Diagnosis of Critical Carotid Artery Disease
The numeric values recorded for age and Peak Systolic Velocity (PSV) were re-coded 
into new categorical variables. The categories used to re-code PSV values into degree of 
stenosis were determined in consultation with the vascular surgeons, and involved 
applying the same treatment to the aggregate dataset as would be used in the 
interpretation of an individual test. Using the PSV cut-offs shown in Table 4, each test 
was labelled as one of four outcomes: normal; 50–69% occluded; 70–99% occluded; and, 
fully occluded. Outcome was further categorized as ‘normal’ or ‘abnormal,’ where 
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abnormal encompassed the clinically significant outcomes of 50–99% occlusion. Stenosis 
greater than 50% is considered clinically significant and in the presence of recent 
symptoms suggestive of cerebral ischemia, will be further evaluated for surgical 
intervention.
Table 4. Degree of stenosis categories derived from peak systolic flow velocity (PSV in cm/s).
Degree of Stenosis Peak Systolic Flow
Normal PSV < 125 cm/s
50–69% PSV 125–230 cm/s
70–99% PSV > 230 cm/s
Fully Occluded PSV 0 cm/s
3.6 Statistical Analysis
Following data preparation and coding, the file was imported into SPSS statistical 
software, version 24.0. Clinically important variables were represented in graphical 
format for visual inspection. Incidence of testing and clinical characteristics of the tested 
population were investigated using descriptive statistics including cross-tabulation and 
the chi-squared test for association. Time-to-access testing during 2015 was evaluated 
using survival analysis including the Kaplan-Meier method. Subsequent monitoring of 
time-to-access in 2016 and 2017 did not involve survival analysis due to limitations in 
data capture. The 2016, 2017 data was collected by another individual and provided as a 
mean value.
Appropriateness of testing/ability to predict diagnosis of critical carotid disease 
were evaluated using several methods. Associations between clinically important 
variables such as admission status, sex, and ‘reason for test’ were analyzed using 
descriptive statistics, including the chi-squared test for association. Binomial logistic 
regression was used to examine the relationship between the dependent variable ‘test 
Abnormal
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outcome’ (normal/stenosis), and the predictor variable, ‘reason for test’ (Table 3). Odds 
ratios (OR) and accompanying significance (p-values) were interpreted to determine the 
odds of a clinically significant outcome (abnormal) with each ‘reason for test,’ admission 
status, and sex.
Phase II Methods – Improving Access to Testing and Referral Quality
Definitions of priority are provided in Table 5. Phase II began with abstraction of 
information from incoming priority 1 and 2 referrals from March to June 2015. Following 
interventions implemented in July 2015, incoming referrals were sampled again, from 
August to December, 2015. Subsequent sampling of incoming referrals was carried out in 
January to May, 2016 and January to June, 2017 to monitor time-to-access. At baseline, 
98 P1 and 99 P2 referrals were assessed. In the period August to December 2015, 136 P1 
and 128 P2 were studied, as were 99 P1, and 119 P2 from January to May, 2016, and 104 
P1 and 139 P2 in January to June, 2017. 
The time-to-access testing was calculated as the number of days from when the 
referral was signed and dated by the referrer, to the test date. If the patient was tested the 
day the referral was written, time-to-access was recorded as zero. Weekends and holidays 
were included as elapsed time. The only exception was if a person was offered an earlier 
appointment but refused it. In such cases, access was calculated using the date the person 
could have been tested rather than a later time at which they elected to be tested. 
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Table 5. Priority categories assigned to referrals at St. Clare’s Vascular Lab 2015–17 with timelines for 
testing with onset of neurological symptoms indicating carotid territory ischemia (unilateral weakness 
(face/arm/leg), speech disturbance/aphasia, or amaurosis fugax.)
Priority Clinical History and Risk Timeline for Testing
P1 Symptom onset within previous 48 hrs Test within 48 hrs of symptom onset
P2 Symptom onset between 48 hrs and 2 wks Test within 14 days of symptom onset
P3 Symptom onset more than 2 wks Elective (next available appointment) 
3.7 Referrals: Critical to Quality (CTQ) Features and Defects
Using observation, process mapping, and facilitated stakeholder workshops, the process 
of accessing carotid artery U/S was deconstructed and documented. Component steps, 
variation(s) in process, and referral defects were analyzed to identify root causes for 
protracted access, and to hypothesize methods of improvement.
The key clinical features required to triage each referral and the information 
required to contact the patient with an appointment are the CTQ elements. According to 
the United States (U.S.) Department of Health and Human Services Quality Toolbox, 
2011, CTQ elements are, ‘those key measurable characteristics of a product or process 
whose performance standards or specification limits must be met in order to satisfy the 
customer (U.S. Department of Health, 2011). Clinical CTQ elements of carotid imaging 
referrals were determined based on Canadian best practice recommendations for the 
prevention of secondary stroke, and include type and timing of symptoms (Figure 5. 
Quality of Care NL Pocket Card). Additionally, the demographic information to 
accurately identify the patient and their referrer were deemed CTQ elements. Using this 
approach, a defective referral was defined as an incoming requisition where CTQ 
elements were missing, illegible, or ambiguous to the point of being impossible to triage. 
A baseline proportion of defective referrals was measured for incoming P1 requisitions. 
Examples of defects are illustrated in Figure 6. 
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Figure 6. Examples of defective referrals received at the Vascular Lab, June 2015. Both requests are 
presumably for carotid artery imaging, though it is not specified. Date of onset, and/or type of symptoms 
are not provided, and legibility is poor in both cases, making these referrals impossible to triage using an 
evidence-based method of risk stratification.
A standardized requisition (Figure 7), purposefully designed to capture CTQ 
elements, was deployed in June 2015. In addition, the vascular lab adopted a standard 
approach to triage and appointment booking, and a practice of ‘spot-checking’ access 
time for P1 and P2 referrals. Staff came to consensus on booking P1 referrals within 48 
hours and P2’s within 14 days. The practice of triaging incoming referrals on an ongoing 
basis rather than allowing them to ‘batch’ for triage every 2–3 days, was established. 
Page 34 | Chapter 3
Figure 7. The carotid imaging portion of the enhanced requisition introduced in June, 2015.
3.8 Knowledge Translation Activities
In partnership with Quality of Care NL, a comprehensive multi-media education and 
knowledge translation (KT) campaign, customized to various stakeholder groups, was 
undertaken. Examples of KT initiatives include, didactic education sessions (in person 
and via webinar); online learning module development; facilitated workshops; printed 
materials such as a quarterly academic publication, posters, and pocket cards; shareable 
slide decks; and, media coverage (television, newspaper, radio, and social media) (Figure. 
8). A panel of patient representatives was engaged to discuss the initiative and to provide 
advice and feedback. KT activities began in June 2015 and continued over the subsequent 
24-month period. Ongoing response was sought from stakeholders using internal 
RHA communication channels such as email and regular stroke and vascular program 
meetings. In addition, feedback mechanisms managed by Quality of Care NL were 
utilized including a public feedback email and subsequent patient panel discussions.
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Figure 8. An example of educational material developed and utilized as a component of the 2015–16 
Quality of Care NL secondary stroke prevention/carotid U/S utilization KT campaign. Used with 
permission of Quality of Care NL.
3.9 Academic Detailing
During 2015–16, peer-to-peer educational outreach, or academic detailing, was led by 
Quality of Care NL. This entailed an individualized audit and feedback initiative led by 
knowledgeable and experienced physicians with the objective of facilitating behavior 
change by referring providers for better quality referrals and more appropriate testing. 
Referrers within the catchment area were provided confidentially with their own Vascular 
Lab carotid U/S utilization history (Figure. 9). This was followed–up with a voluntary 
face-to-face academic detailing visit by Quality of Care physician lead(s), comprising 
visits with 95% of family physicians in Eastern Health. During these academic 
detailing visits, a physician champion with subject matter expertise reviewed referrers’ 
personalized carotid imaging utilization history. Visits were conducted individually or 
in small groups, per clinic. They aimed to orient referrers to the findings of the carotid 
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utilization review in relation to current evidence-based guidelines for test-ordering. 
Academic detailing visits were also used to listen to referrers about the challenges of 
managing the population at-risk for secondary stroke, and to gather feedback on the 
overall process improvement initiative.
Figure 9. Example of an educational resource developed for use within the 2015–16 Quality of Care 
secondary stroke prevention and carotid U/S utilization KT campaign. This figure was also personalized, 
per physician, showing where each referrer ranked within the cohort. Used with permission of Quality of 
Care NL.
To gauge the impact of the interventions, time-to-access carotid imaging and 
incoming referral quality were re-evaluated. In the period immediately following 
implementation of the new requisition, (June-December 2015), incoming referrals were 
consecutively sampled and analyzed for time-to-access and defects/data quality. Results 
of referral quality and time-to-access testing were shared with stakeholders. Time-to-
access was subsequently monitored in 2016 (January-May) and 2017 (January-June) to 
determine whether improvements in time-to-access were sustained. The 2016–17 data 
analysis utilized the same methodology but the referrals were not collected by the writer 
and thus cannot be verified to be consecutive sampling.
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Phase III Methods – eOrder
The third phase of this work was the design, development, and creation of an 
implementation plan for an electronic ordering (eOrder) solution. This work began in 
2017 as a partnership between Eastern Health, Memorial University’s Quality of Care 
NL program, the Newfoundland and Labrador Centre for Health Information, and the 
Government of Newfoundland and Labrador.
A project team consisting of representatives of the partner organizations was 
assembled. The team began engaging with stakeholders, including booking staff, Vascular 
Lab technicians, referring physicians, vascular surgeons, RHA management, information 
technology specialists, researchers, and others. Over multiple workshop sessions 2017–
19, stakeholders were consulted on their experience ordering, triaging, coordinating and 
booking appointments, communicating relevant information, and other aspects of the 
test-ordering process. The information was documented and translated into the technical 
requirements for an electronic test-ordering solution.
When sufficient information was gathered to produce an early version of the 
eOrder tool, workshop sessions were conducted to review a prototype. This enabled 
stakeholders situated remotely to visualize the application, imagine the steps and clicks, 
and suggest necessary adjustments. In May 2019, the eOrder solution underwent final 
testing, and was deployed in October 2019.
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CHAPTER 4 – RESULTS
Phase I – Utilization of carotid artery U/S testing 
4.1 Volume of Testing
The volume of testing performed annually at St. Clare’s Vascular Lab decreased over 
time with an overall 32% reduction from 2008 to 2016, after which annual testing volume 
stabilized. Figure 10 illustrates the volume of annual testing from 2007–2018, (2007 
data represents a partial year). There was no difference between the volume of males and 
females tested each year. 
Figure 10. Volume of carotid U/S testing at St. Clare’s Vascular Lab, 2007–2018. 
Figure 11 illustrates the volume of carotid testing taking place at St. Clare’s Vascular 
Lab, along with testing taking place within Eastern Health using CTA, MRA, and carotid 
U/S at locations other than St. Clare’s Vascular Lab. Data from Eastern Health testing 
sites external to St. Clare’s Vascular Lab was not available prior to 2015. Although the of 
number carotid ultrasounds at St. Clare’s fell by 224 from 2015 to 2018, the number of 
carotid imaging tests done elsewhere in Eastern Health increased by 395.
Page 39 | Chapter 4
Figure 11. Incidence of carotid U/S testing at St. Clare’s Vascular Lab, and imaging conducted at other 
sites within the RHA using CTA, MRA, and U/S from 2015–18. (*External site data available from 2015 
only).
4.2 Clinical Characteristics of the Tested Population
Table 6. summarizes baseline characteristics of the cohort of 19,074 adults tested with 
carotid artery U/S at the Vascular Lab from 2007–2017. The tested population ranged in 
age from 20–101 years, with average age of 65 years and no statistical difference in age 
between men and women. The 61–70 years category was the largest, at 6500 patients 
(Figure 12). Eighty seven % (87%) were outpatients (Figure. 13).
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Table 6. Characteristics of the population tested with carotid U/S at the Vascular Lab, 2007–17.
Total tested population (N=19,074)
Sex Males Females Total
Count (% of total) 9406 (49%) 9668 (51%) 19,074
Ave age yrs (SD) 65.5 (11.1) 65.6 (12.1)
Admitted 1300 (54%) 1099 (46%) 2399
Outpatient 8106 (49%) 8569 (51%) 16,675
Figure 12. Volume of individuals tested with carotid U/S at St. Clare’s Vascular Lab 2007–17 by age group 
(years), N=19,074.
Figure 13. Proportion of carotid U/S testing at St. Clare’s 
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The risk factors documented most commonly by vascular technicians at the time of 
testing are shown in Figure 14. Hypertension (45%), hyperlipidemia (24%), and diabetes 
(20%) were recorded most frequently. 
Figure 14. Most common risk factors documented by vascular technicians at the time of carotid U/S St. 
Clare’s Vascular Lab, 2007–17, N=19,074.
4.3 Appropriateness of Testing
Within the total population, the most common ‘reason for testing’ recorded by vascular 
technicians at the time of the U/S was ‘other,’ recorded for 8380 people (44.0%). The 
next most common reason was ‘cerebrovascular event’ at 6574 (34.5%). When ‘reason 
for test’ was analyzed in relation to admission status, it was observed the most common 
‘reason for test’ among inpatients was ‘cerebrovascular event’ (57%). Figures 15 and 16 
illustrate the volume of carotid testing by ‘reason for test’ within the total and admitted 
population, respectively.
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Figure 15. Volume of all carotid testing by ‘reason for test’ 2007–17 at St. Clare’s Vascular Lab, N=19,074
Figure 16. Volume of carotid U/S testing among admitted patients by ‘reason for test,’ 2007–17 at  
St. Clare’s Vascular Lab, n=2399.
44%
57%
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The total volume of appropriate testing (carried out to investigate an acute 
cerebrovascular event) was 7863, representing 35% of all testing 2007–2019, Figure 23.
Figure 17. Total volume of indicated/appropriate carotid U/S testing at St. Clare’s Vascular Lab from 
2007–19, N=22,167. *Indicated testing is for investigation of Cerebrovascular Event including Stroke, TIA, 
and Amaurosis Fugax.
Figure 18 shows the annual percentage of indicated testing. A trend towards more 
appropriate testing was observed over time between 2007–19 and a chi-squared test for 
association reinforces this observation is not a random finding, c2(10)=79.260, p<0.001. 
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Figure 18. Annual proportion of appropriate carotid artery U/S testing at St. Clare’s Vascular Lab from 
2007–19, N=22,167. *Indicated testing is for investigation of acute Cerebrovascular Event including Stroke, 
TIA, and Amaurosis Fugax. **2019 partial year ends April.
4.3.1 Carotid Ultrasound Results
The majority of the population had a normal outcome. Of 19,074 people tested, 71.4%, 
(n=13,621) had a normal result, and 28.6% (n=5453) had clinically significant carotid 
stenosis or occlusion (Figure 19). 
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Figure 19. % patients with abnormal carotid artery tests
Table 7 illustrates the proportion of clinically significant carotid stenosis by admission 
status. Abnormal findings occurred more frequently in admitted patients, and this 
association was statistically significant (χ2 (1) =43.94, p<0.001). (Figure 20).
Table 7. Proportion of patients with normal/abnormal carotid ultrasound within the tested population at 
St. Clare’s Vascular Lab, 2007–17, sub-divided by admission status.
Total Tested Population (N=19,074)
Outcome Abnormal Normal Total P-value
Inpatient (% of Inpatients) 823 (34%) 1576 (66%) 2399
Outpatient (% of Outpatients) 4630 (28%) 12,045 (72%) 16,675 <0.001
Total 5453 (28.6%) 13,621 (71.4%) 19,074
28.6%
71.4%
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Figure 20. % with abnormal carotid tests within the admitted sub-group tested with U/S at St. Clare’s 
Vascular Lab, 2007–17, n=2399.
Table 8 shows the total number of females ‘vs’ males tested was similar, but there was 
a significantly higher proportion of males with an outcome of critical stenosis, p<0.001. 
This is illustrated in Figure 21 below. 
Table 8. Comparison of critical carotid disease in males and females tested with carotid U/S at St. Clare’s 
Vascular Lab, 2007–17.
Sex Males Females Total Significance
Stenosis (% of total) 2906 (15.2%) 2547 (13.4%) 5453 (28.6%)
p<0.001
Normal (% of total) 6500 (34.1%) 7121 (37.3%) 13,621 (71.4%)
Count (% of total) 9406 (49.3%) 9668 (51.0%) 19,074
28.6%
71.4%
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Figure 21. Carotid U/S testing at St. Clare’s Vascular Lab, 2007–17, showing differences in outcome by sex, 
N=19,074.
4.3.2 Critical Carotid Disease by Reason for Testing
Figure 22. Illustrates, the volume of testing carried out for each ‘reason for test’ showing 
the proportion of normal and abnormal outcomes within each testing category. Within the 
appropriate test group (had a cerebrovascular event), rate of diagnosis of critical carotid 
disease was 33% and in those referred because of a carotid bruit it was 44%. In those 
who did not have symptoms arising from the carotid artery territory the rate was 27.1% 
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Figure 22. Volume of carotid U/S testing at St. Clare’s Vascular Lab by reason-for-test, showing outcome 
of testing per reason, 2007–17, N=19,074.
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4.3.3 Prediction of Critical Carotid Disease Using Clinical Data
The dichotomous response variable investigated using regression analysis was, ‘test 
outcome’ (normal or abnormal). Reason for test, (five mutually exclusive options), sex 
(male or female), and admission status (inpatient or outpatient) were entered as predictor 
variables. Results of the regression analysis are summarized in Table 9. 
Table 9. Results of multiple logistic regression analysis of relationship between ‘reason-for-test’, ‘sex’, and 
‘admission status’, and ‘outcome’ in carotid U/S testing at St. Clare’s Vascular Lab, 2007–17, N=19,074.
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
95% C.I. for EXP(B)
 Lower Upper
Reason   315.017 4 p<0.001  
Carotid Bruit 0.768 0.089 73.769 1 p<0.001 2.156 1.809 2.569
Cerebrovascular 
Event 
0.230 0.073 9.840 1 0.002 1.259 1.090 1.454
Other 0.054 0.072 0.563 1 0.453 0.947 0.822 1.092
Vertigo 0.587 0.093 40.256 1 p<0.001 0.556 0.464 0.666
Male 0.209 0.032 41.268 1 p<0.001 1.232 1.156 1.313
Inpatient 0.236 0.048 24.578 1 p<0.001 1.266 1.153 1.390
Constant 1.119 0.070 256.319 1 p<0.001 0.326   
*Using Asymptomatic, Outpatient, and Female as reference categories
The analysis indicates abnormal results were two times more likely when the ‘reason 
for test’ recorded was ‘Carotid Bruit’, (OR 2.156, p<0.001). An abnormal result was 
approximately half as likely when ‘Vertigo’ was recorded (OR 0.556, p<0.001), 26% 
more likely when the recorded reason was ‘Cerebrovascular Event’ (OR 1.259 p<0.001) 
and ‘other’ was not statistically significant. Males had a 23% increased likelihood of an 
abnormal outcome, (OR 1.232, p<0.001), and inpatients had 27% increased likelihood of 
having a clinically significant carotid stenosis (OR 1.266, p<0.001).
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Phase II Results – Interventions to Improve Access and Referral Quality
4.4 Time-to-Access Carotid Artery U/S Imaging
Measurements of access time were obtained over four sampling episodes between March 
2015 and June 2017. Mean time-to-access testing by priority level is shown in Figure 23 
and Figure 24 for P1 and P2 referrals during each of the four periods. For high priority 
patients who had recent neurological symptoms, and for whom testing was recommended 
within 48 hours, mean time to U/S at baseline was 9 days. Following interventions it was 
reduced to 3.1 days. For P2 patients who had neurological symptoms more than 48 hours 
ago and required testing within 48 hours to 14 days, on average, time-to-access at baseline 
was 41 days. After interventions the target P2 access time was achieved, at 10 days.
Figure 23. Average time (days) to access carotid U/S at St. Clare’s Vascular Lab for Priority 1 referral over 
four periods of manual sampling 2015–17, n = 98, 136, 99, and 104 for each period, respectively.
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Figure 24. Average time (days) to access carotid U/S at St. Clare’s Vascular Lab for Priority 2 referrals over 
four periods of consecutive sampling 2015–17, n = 99, 128, 119, and 139 for each period, respectively.
Time-to-event analysis was carried out for the data collected in 2015 using 
a consecutive sampling process. The outputs of the time-to-event analysis using the 
Kaplan-Meier method are found in Table 10 and 11. Mean and median time to access 
carotid U/S are given for P1 and P2 referrals during the baseline data collection period 
(March-May 2015), in comparison to after process and referral changes (July-December 
2015). The significance of the log-rank tests in both cases (p<0.001) supports rejecting 
the null hypothesis: that there is no difference in the time to access U/S between baseline 
and after the interventions. For P1 patients, no individuals were accessing carotid U/S 
within the target of 48 hours of symptom onset at baseline, and 14% were within the 2 
day target after the interventions were implemented. Within the P2 group, at baseline 
no patients were receiving a test within 2 weeks and following the interventions, 9% 
accessed testing within the target 14 days. It was not possible to carry out time-to-event 
analyses on subsequent testing in 2016/17, as data from these periods were available in 
aggregate form, as mean values only.
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Table 10. Time-to-event from date of referral to date of appointment for P1 patients at baseline and post-

















Post 5.794 .298 5.210 6.379 5.000 .275 4.462 5.538
Pre 9.153 .755 7.673 10.633 7.000 .429 6.159 7.841
Overall 7.201 .376 6.000 .235 5.538 6.462
Chi-Square df Sig.




Estimate Std. Error Estimate Std. Error Estimate Std. Error
Post 7.000 .576 5.000 .275 3.000 .271
Pre 11.000 1.398 7.000 .429 4.000 .323
Overall 8.000 .563 6.000 .235 5.000 .253
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Table 11. Time-to-event from date of referral to date of appointment for P2 patients at baseline and post-

















Post 21.898 .644 20.636 23.160 21.000 .707 19.615 22.385
Pre 41.480 1.22 39.088 43.871 37.000 .521 35.979 38.021
Overall 30.389 .911 28.604 32.174 29.000 1.542 25.978 32.022
Chi-Square df Sig.




Estimate Std. Error Estimate Std. Error Estimate Std. Error
Post 26.000 .320 21.000 .707 16.000 .330
Pre 43.000 1.016 37.000 .521 35.000 .323
Overall 37.000 .546 29.000 1.542 20.000 1.106
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Figure 25. Kaplan-Meier survival function for P1 patients at baseline (March-May 2015) and post process 
improvement interventions July-December 2015.
Figure 26. Kaplan-Meier survival function for P2 patients at baseline (March-May, 2015) and post process 
improvement interventions (July-December, 2015).
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4.4.1 Referral Quality
Following the implementation of a standard requisition, and interventions to educate 
referrers on CTQ elements of incoming requisitions, referral quality was re-evaluated. 
The findings are summarized in Figure 27. Evaluation of incoming requisitions using 
the standard form indicated: onset date and time and type of symptoms were very much 
more likely to be provided (15% v. 88%) and twice as legible (42% v. 87%) following 
implementation of the standardized requisition form. It was observed that some referrers 
continued to submit requisitions without completing mandatory fields, and/or crossed 
out the form’s field labels and entered their own data. Wherever data was hand-written, 
legibility was an issue. 
Figure 27. Defects in P1 requisitions received at St. Clare’s Vascular Lab for carotid U/S testing at baseline, 
and following implementation of a standard requisition, (n=98 referrals in March-May, 2015, and n=136 
from July-December, 2015). *Some requisitions had more than one defect.
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Phase III Results
4.5 eOrder Requirements
The objective of phase III was to document system enhancements supporting improved 
efficiency and appropriateness of testing, including requirements for an electronic 
ordering solution. The results of the requirements-gathering sessions are documented and 
themed in Table 12, according to the priorities of each major stakeholder group.
Five basic requirements were identified by point-of-care clinical and administrative 
stakeholders as mandatory elements for an eOrder system:
1. Software must be web-enabled/accessible from multiple locations.
2. It must be possible to modify the electronic ordering software in response to 
changes in best practice recommendations and/or logistical changes in ordering 
processes.
3. The electronic ordering solution must be secure and capable of ensuring industry-
standard privacy and confidentiality requirements upheld.
4. The solution must be sufficiently fast so as not to impose delay on usual clinical 
procedures. 
5. The solution must be capable of safely supporting prioritization of incoming 
referrals in real-time and on a continuous basis, therefore requiring an internal 
triage algorithm.
Two additional items of high importance identified by stakeholders were the capacity 
for immediate scheduling and notification of appointment, and the ability to access the 
eOrder tool through a single organizational sign-on or login process. 
Aside from identifying requirements for a future eOrder tool, stakeholders were 
also consulted on communication and implementation plans for the new software. Their 
recommendations are summarized in Tables 12 and 13.
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Table 12. Themed requirements/functionality for the eOrder tool, as identified by stakeholders during 















Legibility    
Mandatory and/or 
Constrained Data 
Fields, Minimal Free 
Text
   
Risk Stratification 
Embedded in Order    
Immediate Scheduling      
Secure and Private       
Modifiable       
Single User Sign-On     
Interoperable with 
eHealth Systems     
Cost-Effective  
Configurable, 
Customizable     
Role-Based Access   
Rapid Performance    
Web-Enabled       
Searchable  
Mobile-Ready    





Waitlist Management     
Data Visualization, 
Trending     
Print Worklist    
Page 58 | Chapter 4
Table 13. Recommendations provided by stakeholders during eOrder consultation sessions 2018–19 
regarding future eOrder communication and implementation strategy.
Ensure software performs rapidly and accurately, (no glitches or impediments to clinical workflow) 
before launch takes place.
Use incoming referrals at the Vascular Lab to ‘test’ usability of the tool before embarking upon a live 
launch.
Carry out a ‘soft’ launch first to identify challenges and mitigate user frustration
When early users are satisfied with the eOrder tool, expand the launch to widespread access across the 
province.
Provide change management support at the Vascular Lab full-time for the first 2 weeks following launch 
of the eOrder tool
Begin communicating about eOrder prior to soft launch using one-pager fact sheet.
Have an identified “change champion” reach out personally to the soft launch group to invite and 
encourage their participation.
Ensure the soft launch captures a variety of ordering environments including primary care, emergency 
departments, and acute care.
Select a firm target date after which paper forms will no longer be accepted at the Vascular Lab.
Communicate the end of paper requisitions at the Vascular Lab extensively within the referring provider 
group.
Create help resources for all user groups including referrers, and the Vascular Lab administrative and 
technical staff.
Plan sessions for core group to share experiences and troubleshoot issues at key points post soft launch.
4.5.1 Electronic Requisition Form
The electronic requisition form was deployed in October 2019 using the provincial 
electronic health record, known as HealtheNL, as the access point. Screenshots of the 
eOrdering tool are provided in the appendix.
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CHAPTER 5 – DISCUSSION
The primary objective of this research was to analyze the utilization of carotid artery U/S 
imaging at the Vascular Laboratory operated by Eastern Health at St. Clare’s hospital 
within four areas: 
1. volume of testing; 
2. clinical characteristics of the tested population;
3. appropriateness of testing; and, 
4. time-to-access testing. 
A secondary objective was to describe system enhancements supporting improved 
efficiency and appropriateness of testing, including requirements for an electronic test-
ordering solution. Acknowledging this is a mixed methods analysis lacking the rigor 
necessary for attributing cause and effect, the findings do support the hypothesis: In 
a local testing facility, processes of care for accessing carotid artery imaging using 
Doppler U/S in the management of adults presenting acutely with symptoms of carotid 
territory ischemia can be improved to enhance access for high priority patients.
The results are discussed below in reference to the literature and locally 
significant factors.
5.1 Utilization of testing
From 2007–2019, a substantial number of adults (N=22,167) had carotid artery U/S 
testing at St. Clare’s Vascular Lab. This analysis indicates only 35% of all testing 
was for an appropriate reason: neurological symptoms arising from the carotid artery 
territory. Referral because of a carotid bruit (6%) and the remaining 59% (other, vertigo/
dizziness, and asymptomatic) may be considered inappropriate because no surgical 
intervention would be considered in an asymptomatic patient. Even in the event of 
diagnosis of high-grade stenosis, this 65% of testing was not associated with recent 
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symptoms suggestive of carotid artery stenosis or carotid territory ischemia, and 
therefore these patients would not be eligible for revascularization. From a clinical 
perspective, inappropriate testing creates a line-up/wait-list, likely to interfere with 
access to testing for those patients who do need it urgently. 
Each U/S requires approximately 45 minutes of direct technician effort, along 
with usage of equipment and administrative support for booking and registration. 
Following the test, a vascular surgeon interprets the results, dictates a consultation 
report, and forwards the information to the referring provider. A conservative estimate 
is 60 minutes of collective time and effort per test. The additive impact of over 14,000 
potentially unnecessary U/S studies, at 60 minutes each, encompasses a significant outlay 
of highly specialized health system resources. The published cost of an extra-cranial U/S 
in a Canadian facility ranges from $55 to $525, (Government of Ontario, 2015). At these 
rates, inappropriate U/S testing at the Vascular Lab between 2007–19 had direct cost of 
approximately $0.8–$7.5 M. 
5.1.1 Cost of Stroke 
Examining cost from a preventative perspective, the primary purpose of extra-cranial 
imaging is to identify candidates who may require re-vascularization to prevent a secondary 
stroke. One prevented stroke saves approximately $74,000 in the first twelve months after 
the event (Mittmann et al., 2012). If carotid testing led to 500 re-vascularization procedures 
over 10 years, at a NNT of 5 patients (within 14 days of symptom onset), 100 prevented 
strokes avoids a minimum of $7.4M, accounting only for the cost of the first year for each 
event. These simple financial calculations provide even greater perspective to the well-
established recommendations for timely access to carotid imaging. 
While this research does not examine the local relationship between incidence 
of secondary events and delayed testing, the results do show substantial inappropriate 
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testing as well as delayed access for highest priority patients. It is reasonable to assume 
that significant amounts of inappropriate testing ‘clogs’ access to imaging for those 
who need it rapidly to determine their need for surgical re-vascularization, thereby 
contributing to higher rates of secondary stroke. The low annual volume of carotid 
endarterectomy carried out in the province, 61 cases/year from 2013–18, reinforces this 
assumption, though further review is required in this area along with an examination of 
access to carotid testing and carotid endarterectomy, and incidence of stroke in relation to 
where people live within the province.
5.1.2 Need for Imaging
Given the substantial time, expertise, cost, and the importance of timely imaging to 
secondary stroke prevention, it is critical that health systems carefully manage access to 
carotid testing. Responsible stewardship of this resource ensures those who need a test 
can access one rapidly, and those who do not require testing are not utilizing resources 
unnecessarily and blocking access for those who do. In keeping with this, Choosing 
Wisely Canada, and its American counterpart, have released recommendations advising 
against carotid testing in the absence of acute carotid territory symptoms (Choosing 
Wisely Canada, 2018; Scott et al., 2014). Their local counterparts, Choosing Wisely NL 
and Quality of Care NL, are also actively pursuing appropriate care in this area (Figure 8).
The high prevalence of cardiovascular risk factors in the province, along 
with aging of the population, indicate substantial risk of stroke in Newfoundland 
and Labrador’s general population. Sixty-three per cent of residents over the age of 
twelve has at least one chronic condition and rates of diabetes, hypertension, obesity, 
and smoking are among the highest across all Canadian jurisdictions (Government of 
Newfoundland and Labrador, 2015). Almost 70 per cent of people in the province are 
overweight or obese, 50 per cent are not getting the recommended amount of physical 
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activity, and over 20 per cent of the population smokes (Government of Newfoundland 
and Labrador, 2015). Newfoundland and Labrador’s population is aging faster than any 
other jurisdiction in Canada; in 2011, 16 per cent of the province was over the age of 65, 
with projections of continued ‘graying’ of the population (Government of Newfoundland 
and Labrador, 2015). The incidence of hospitalized stroke in Newfoundland and Labrador 
is higher than the Canadian average, at 161/100,000 compared to 142/100,000 in 
Canada (Canadian Institute for Health Information, 2019). Secondary stroke is also more 
common within the province at 19%, in comparison to 12% nationally (Heart and Stroke 
Foundation of Canada, 2011).
5.1.3 Decreased Testing at the Vascular Laboratory
Despite an aging population at increasingly high risk for stroke, the volume of testing 
performed annually at St. Clare’s Vascular Lab was observed to be decreasing from 
2007–15 and between 2016–18, annual testing volume stabilized. In keeping with a 
growing burden of chronic disease in a rapidly aging population, a stable or increasing 
volume of annual testing would be anticipated at the vascular lab. This was not observed 
until 2016/17, the period immediately following the initiation of a provincial process 
improvement targeting secondary stroke prevention. A key component of the initiative 
was awareness and recognition of signs and symptoms of stroke and TIA, by both the 
public and health care providers. Specific emphasis was placed upon the importance of 
rapid initiation of investigations in the presence of acute, localizing, carotid territory 
symptoms. The apparent stabilization in annual volume of carotid testing at the Lab after 
2016 may be cautiously interpreted as a response to the process improvement efforts. In 
consideration of this information, it is important to note that vascular testing also takes 
place at sites external to the Vascular Lab. Data on incidence of carotid imaging outside 
the lab is only available after 2015 and indicates an upturn in testing, particularly in usage 
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of CTA (Figure 11). This is an important observation in view of the considerable effort 
applied to improving access to carotid imaging for appropriate patients, beginning in 2015.
A possible explanation for reducing annual test volume at the Vascular Lab from 
2007–15 is concurrent increase in the use of CTA testing at external sites. While the data 
in Figure 11 suggest this to be the case it cannot be confirmed, as CTA utilization for the 
complete study period is not available. An increase in CTA utilization is in keeping with 
the growing body of evidence recommending its use as the first line imaging modality 
for hyperacute investigation of TIA and non-disabling stroke (Wintermark et al., 2013). 
Efforts to increase awareness of appropriate TIA management, including imaging, have 
been ongoing both within the broad medical community, and locally. Agencies like the 
Canadian Heart and Stroke Foundation (Canadian Stroke Best Practice Recommendations), 
and the American Heart and Stroke Association (Get with the Guidelines), have undertaken 
substantial campaigns to disseminate evidence and tools supporting guidelines-based care 
(Heart and Stroke Foundation of Canada, 2018; American Stroke Association, 2019). 
Some uptake of knowledge from these efforts would be expected, possibly resulting in 
increased use of CTA, decreased use of U/S, and improved appropriateness.
In contrast to the argument that declining annual carotid U/S volumes is due 
to improved use of CTA , the decline may also be attributed to poor recognition of 
and reaction to high risk symptoms by the general public, and suboptimal practice 
patterns within the referring population. The latter can be neither confirmed nor refuted 
without the ability to reconcile the total number and timing of high-risk carotid territory 
presentations in primary care and/or emergency settings, against referrals for carotid 
testing. In other words, an answer is required to the following question: are all people 
presenting with symptoms of acute carotid territory ischemia being referred for extra-
cranial imaging (via U/S, CTA, and/or MRA)? This question is under consideration for 
future quality improvement efforts within the local region.
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5.2 Clinical Characteristics of the Tested Population
The average age within the tested population was 65 years for both sexes. The largest age 
category was 60–70 years, and the next largest was 70–80 years. There was no statistical 
difference in the volume of men and women tested, but fewer females were tested within 
the two largest age categories (60–70 and 70–80 years), and in the youngest and oldest 
age groups there were more females tested. These findings are partially consistent with 
documented age and sex-related trends in stroke incidence. 
Risk of stroke generally increases with age and stroke is slightly more common in 
women at particular stages of life. Women are at higher risk in their younger years due to 
reproductive physiology, and in their later years due to longer life expectancy (Benjamin 
et al., 2018; Harvard Health Publishing, 2014). The observation that women are under-
represented locally in the two largest volume categories is concerning, as women are 
expected to be at the same or higher risk for stroke at all ages. This observation suggests 
disparity in access to testing between males and females and raises important questions 
about local recognition and reaction to high-risk symptoms in women, and management 
of women by the local health care system. Such findings are not unique to this region. 
Recent reports by the Heart and Stroke Foundation of Canada and the American Stroke 
Association point to a gap in womens’ ability to access services equitably, and differences 
in stroke outcomes between males and females (American Stroke Association, 2019; 
Heart and Stroke Foundation of Canada, 2018). In keeping with the reports, these local 
results demonstrate women access testing less frequently between the ages of 60–80, 
when stroke risk is highest for both males and females, and when the majority of testing 
takes place at the local facility. Future quality improvement work should explore root 
causes and solutions to mitigate this disparity. 
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5.2.1 Risk Factors
Figure 11. lists the most common risk factors/co-morbid conditions recorded by vascular 
lab technicians at the time of carotid U/S. As this information is by self-report, it must 
be interpreted with caution; however, findings are in keeping with risk factors/co-
morbidities for stroke reported in the literature (Boehme, 2017; Madsen et al., 2018). 
Hypertension, the most contributing risk factor for stroke, was documented for over 40% 
of the tested population, followed by hyperlipidemia in 20% of those tested, diabetes in 
18%, and smoking in 13%. Aside from the issue of self-report impacting data quality, 
an additional concern in the interpretation of this information is lack of standardization 
and use of strict definitions by vascular technicians during data collection. For example, 
smoking is anticipated to be under-estimated in this data. This is due to known issues 
with disagreement between self-report of smoking status and gold standard testing for 
exposure to nicotine, and variability in the interpretation of ‘quit’ by both technicians 
and patients (Zhang et al., 2016). When documenting risk factors, vascular technicians 
were not working from a standard definition of ‘quit.’ Many people later divulge they 
‘quit’ smoking the day of their test. Similarly, in the data it is not possible to differentiate 
between Type I or Type II Diabetes, because ‘type’ is not documented. The impact of lack 
of standardization in the collection of risk factor (and other) data is reduced confidence in 
the validity of findings.
5.3 Appropriateness of Testing
According to the Canadian Medical Association (CMA), appropriateness encompasses 
‘the right care, provided by the right providers, to the right patient, in the right place, 
at the right time, resulting in optimal quality care’ (Canadian Medical Association, 
2015). The CMA further describes appropriateness according to five key components, 
summarized in Table 12.
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Applying the CMA’s definition, the results of this research demonstrate a 
substantial amount of inappropriate carotid testing stemming from testing patients 
without sufficient indication; and, testing patients outside recommended timeframes. 
It might also be argued that a lack of robust QI/QA practices to identify and address 
declining annual test volumes and defective incoming referrals also constitutes 
inappropriate service delivery, as per CMA’s definition.
Table 14. Components of appropriate care, adapted from Canadian Medical Association, 2015.
 Each individual tested has a ‘reason for test’ recorded by vascular technicians at 
the time of their carotid U/S. The most commonly recorded ‘reason’ from 2007–17 was 
‘other,’ a highly non-specific indication for testing, recorded in 8380 encounters. For the 
complete dataset 2007–2019, in 65.5% of all testing, the documented ‘reason for test’ 
was for a non-indicated issue i.e., vertigo/dizziness/syncope, carotid bruit, asymptomatic, 
or other. This finding is consistent with Keyhani (2016), who found of 4124 carotid 
U/S, only 5.4% were for a clearly indicated reason and the remaining 94.6% were for 
uncertain, or frankly inappropriate reasons – the most common of which were carotid 
bruit, vascular risk factors, and dizziness/syncope.
Dimensions of Appropriate Care
1. Right care is based on evidence for effectiveness and efficacy in the clinical literature 
and covers not only use but failure to use; 
2. Right provider is based on ensuring the provider’s scope of practice adequately meets 
but does not far exceed the skills and knowledge to deliver the care; 
3. Right patient acknowledges that care choices must be matched to individual patient 
characteristics and preferences and must recognize the potential challenge of 
reconciling patient and practitioner perceptions; 
4. Right venue emphasizes that some settings are better suited in terms of safety and 
efficiency to delivering a specific type of care than others; 
5. Right time indicates care is delivered in a timely manner consistent with agreed upon
Page 67 | Chapter 5
The high incidence of testing for inappropriate reasons observed in these results 
may be related to current and historical inconsistency between various sets of North 
American practice guidelines (Wintermark et al., 2013). Despite Level A evidence 
supporting the use of extra-cranial imaging in the presence of acute localizing carotid 
territory symptoms, a number of organizations continue to publically endorse the practice 
of broad carotid artery screening (Wein et al., 2017). According to the Radiological 
Society of North America (2019), “Joint guidelines issued by the American College 
of Cardiology Foundation, American Heart Association, American Stroke Association 
and other healthcare groups suggest that carotid duplex US may be considered 
for asymptomatic patients who have peripheral artery disease, coronary artery disease, 
atherosclerotic aortic aneurysm, or at least two risk factors for stroke.” In contrast, current 
Canadian Best Practice Recommendations specify the use of extra-cranial imaging for 
symptomatic patients i.e., in the presence of acute, localizing, carotid territory symptoms 
(Wein et al., 2017; Heart and Stroke Foundation Canada, 2018). As Nguyen et al., (2018) 
summarize, the Canadian recommendations are concordant with international guidelines.
Given the pervasive practice of asymptomatic carotid artery screening and 
subsequent surgical revascularization in the U.S., a number of organizations have 
released public statements recommending against this low value and potentially harmful 
care. The U.S. Preventive Services Task Force has a recommendation against carotid 
screening in adult asymptomatic patients (U.S. Preventative Services, 2014). Carotid 
imaging in asymptomatic populations is described as a low-value test, appearing on 
multiple “Choosing Wisely” campaign lists (American Academy of Family Physicians, 
2019; American Academy of Neurology, 2013; Choosing Wisely Canada, 2018). Keyhani 
et al., 2016, state, ‘reducing inappropriate carotid imaging may stem a pipeline of low-
value care because many patients who are subsequently re-vascularized received initial 
imaging for reasons considered inappropriate.’ 
Page 68 | Chapter 5
In this analysis, 35.5% of testing was carried out with ‘reason for test’ 
documented as cerebrovascular event i.e., TIA or stroke. This suggests approximately 
one third of testing at the Vascular Lab was carried out for indicated/appropriate reasons 
however, without the time/date of symptom onset, it is unknown whether testing was 
within the recommended timeframe. Extrapolating from the small subset of manually 
collected data on ‘time-to-access’ testing, it is reasonable to assume prolonged access was 
an existing issue within the total population tested, regardless of ‘reason for test’. This 
is corroborated by key informant interviews with Vascular Lab staff indicating that often 
patients whose referral suggested carotid territory ischemic event may have had symptom 
onset quite remote to the time of the test. It is suspected that a substantial proportion of 
the 35.5% were outside the timeline within which surgical intervention is recommended, 
and therefore a finding of carotid stenosis would not change their clinical course. Thus, 
35.5% is anticipated to be an over-estimation of true appropriateness. In keeping with 
these findings, in their 2016 analysis of over 4000 carotid imaging cases, Keyhani et al., 
judged only 5.4% of tests as appropriate, 83% uncertain, and 11% inappropriate. Also 
consistent with the findings of this work, Keyhani et al., found the most common reasons 
for test-ordering to be: carotid bruit, multiple vascular risk factors, dizziness/syncope/
vertigo, and routine follow-up post-surgery. While these results point to a significant and 
possibly long-standing local issue with appropriateness and utilization of carotid imaging 
resources, they also highlight vast potential for improved stewardship with relatively little 
effort and low-cost intervention.
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5.3.1 Predictors of Critical Carotid Artery Disease
The independent risk factors for diagnosis of critical carotid artery disease were being 
male, an inpatient, having had a cerebrovascular event, or, the presence of a carotid 
bruit. The relatively poor predictive power of these variables suggests that asymptomatic 
carotid disease was quite prevalent in the tested population and the clinical description of 
a cerebrovascular event provided by the referring provider was questionable.
 The population tested was primarily outpatient. This is in keeping with the 
protocol used across many jurisdictions in North America and Europe, of managing 
TIA and non-disabling stroke in outpatient settings except in the case of crescendo TIA 
(Lavallee et al., 2007; Rothwell et al., 2007). Based on this approach, one would expect 
the population of admitted individuals to be at higher risk, likely being comprised of 
patients having frequent highest risk acute carotid territory events. It follows that the 
probability of abnormal carotid findings would also be high in the admitted group. This 
outcome was observed in the descriptive data and multiple logistic regression analysis, 
indicating admitted patients were more likely to have abnormal carotid findings than 
those managed in the community (OR 1.266, p<0.001). 
Within the admitted group, the most common ‘reason for test’ recorded was 
‘cerebrovascular event ’, (n=1377) followed by ‘other’ (n=813). The substantial number 
of people given a carotid U/S for reason ‘other’ suggests a mismatch between the 
evidence and current practice, and/or non-standard clinical documentation practices. 
Again, these issues are not surprising, given the absence of clear region-wide protocols 
for managing TIA and/or non-disabling stroke. Key informant interviews reinforce this 
assumption. A repeating theme was frustration with the practice of admitting patients 
for the purposes of arranging carotid testing, an investigation that can be readily carried 
out at the time of initial head CT, and/or at a later date as an outpatient. There is a well-
established body of literature supporting the use of algorithmic tools such as CODE 
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TIA protocols for guideline-based management of TIA (Dutta, D., 2015; Jeerakathil et 
al., 2014). Such algorithms create an evidence-informed care pathway that facilitates 
community management of most patients and admission only for highest-risk individuals. 
It is anticipated that local implementation of CODE TIA would lead to fewer unnecessary 
admissions and improved utilization of carotid imaging resources, including timely 
access for highest-risk individuals. 
5.4 Time to Access Imaging
Various themes emerged within the process improvement activities hypothesized to be 
contributing to prolonged time-to-access testing. These included: the use of multiple 
sub-optimal paper requisitions; high frequency of defective referrals; reduced awareness 
of/reaction to stroke risk by the general public; limited adherence to evidence-based 
timelines by referrers; variable triage and appointment booking procedures at the 
Vascular Lab; and, impaired ability within the Vascular Lab to monitor and balance 
demand and capacity.
Prior to Phase I interventions, baseline measurement of time-to-access indicated 
patients categorized as P1 or P2 were accessing investigations substantially outside 
recommended timeframes. Somewhat ironically, P3 patients, referred for elective 
screening, were the only group accessing testing within recommendations. This being the 
case because there is no clear consensus on screening for carotid stenosis, and therefore 
no time guideline to follow. Time-to-access testing improved considerably in both P1 and 
P2 groups following Phase I interventions, and reductions in access time were sustained 
at follow-up testing January-June, 2017. 
While time-to-access was markedly reduced, Vascular Lab staff reported 
frustration that the wait time for a test could not be decreased further, and acknowledged 
that extensive effort and vigilance is required to maintain timely access. The process of 
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fax, manual triage, booking of appointment, and contacting the patient and/or referring 
provider with appointment is extremely sensitive to defects, disruption, and delayed 
access. One example illustrating this is the newly adopted practice of having the Vascular 
Surgeon on-call triage incoming referrals daily, rather than the legacy practice of allowing 
referrals to ‘batch’ for a few days. Even in the new approach, if daily triage doesn’t occur 
until after-hours due to the on-call physician’s schedule, an individual’s referral may sit 
for an entire day before it is triaged. Similarly, referrals received on a Friday that are 
not triaged until after the weekend will be at least 48 hours old before the person can be 
booked for their test.
Findings of prolonged access times for carotid imaging are not unique to this 
study. Multiple published research efforts have confirmed delayed access to imaging, 
and delays in other components of hyperacute secondary stroke prevention, to be a 
widespread issue. Fairhead et al., (2005), report mean wait for carotid imaging at 33 
days. McCabe et al., (2014), report mean wait of 13.4 days. While the evidence is clear 
that delayed access to care is a pervasive problem, the literature is less clear on why 
delays occur. In a recent Canadian review, Blacquiere et al., (2013), reported median 
time from symptom onset to carotid endarterectomy as 76 days and described multiple 
process delays, particularly in the transfer of care between specialists (e.g., Neurology to 
Vascular Surgery.) Based on the findings of key informant interviews and focus sessions, 
it would appear similar issues exist locally. Stakeholders described routine experiences 
with misdirected faxes; incoming referrals lacking sufficient information for triage; 
difficulty reaching individuals to arrange imaging appointments; and, lack of alignment 
in prioritization approach across various health sectors (ED, DI, Vascular Surgery, and 
Neurology).
In response to the well-documented problem of delayed access to carotid imaging 
and other components of secondary stroke prevention, the literature supports streamlining 
Page 72 | Chapter 5
care using clinical pathways and protocols. The 2010 work of Wasserman et al., 
demonstrates compelling improvements in predicted stroke risk with the implementation 
of a guidelines-based TIA management protocol. Similarly, in their 2018 study, Jarhult 
et al., implemented a TIA management protocol and showed improved efficiency and 
reduced utilization of health care resources without compromise to patient safety.
While these examples of rapid, guidelines-based, TIA management show promise, 
it must be acknowledged that protocols relying on paper processing will continue to 
carry inherent limitations. Legibility problems, inability to constrain responses or make 
fields mandatory, chances of loss or misdirection, and the need for manual handling of 
paper cannot be avoided and almost certainly contribute to inefficiency. With a growing 
appreciation of the shortcomings of paper, it is not surprising that electronic record-
keeping and digital methods of exchanging health information are becoming increasingly 
well-established in clinical practice. In particular, the use of embedded logic, designed 
to prompt optimal care or, ‘clinical decision support’ within medical software is gaining 
traction in many areas of health care (Canada Health Infoway, 2019). 
5.5 Electronic Ordering – eOrder
The inability to answer the previously posed question of ‘what is an optimal rate of 
imaging in a given population’ and, current challenges in the ability to evaluate practice 
patterns in or near real-time, underscores the importance of creating health information 
infrastructure and processes capable of supporting quality assurance/improvement. 
In Newfoundland and Labrador, health data capture occurs using a variety of 
disconnected paper and electronic systems, across sectors, and across the health care 
continuum. There is a growing trend towards the use of electronic record-keeping and 
improved interoperability between systems, however legacy software components 
are often not compatible with each other, impeding information exchange. Taking the 
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example of carotid imaging, an emergency department presentation may result in a paper 
record (later scanned as an image), and/or presenting information may be captured within 
the Meditech hospital information system. For a primary care presentation, clinical 
history is documented on paper or within an electronic medical record. In either case, 
the key elements required for quality monitoring (type/timing of symptoms and date/
type of referral) are isolated, and cannot readily be reconciled against incoming imaging 
referrals. This reality should inform future decision-making regarding clinical tools and 
electronic infrastructure. In a clinical program providing a highly time-sensitive, and 
medically necessary service, the ability to monitor and adjust capacity and process based 
on real-time demand is of critical importance.
A secondary objective of this initiative was to describe system enhancements 
supporting improved efficiency and appropriateness of testing, including requirements 
for an electronic test-ordering solution. While research on the use of electronic health 
tools in hyperacute stroke management is limited, the work of Ranta and colleagues 
provides preliminary evidence for the benefits of digitized pathways and electronic 
clinical decision support tools in secondary stroke prevention (Ranta et al., 2015). 
Using guidelines-based algorithms embedded within digital practice software, Ranta 
et al., (2015) demonstrated improved access to care, and enhanced adherence to 
recommendations without reducing safety or interfering with privacy and security of 
information. In another example, Karlsson et al., (2018) showed improved adherence to 
guidelines-based care by using an electronic decision support tool to increase rates of 
anti-coagulation in patients with atrial fibrillation at risk of stroke. 
Based on these objective results, and stakeholder requirements gathered 
throughout the initiative, the eOrder software for carotid imaging should be both a test-
ordering mechanism and a clinical decision support system. The eOrder software should 
also provide real-time guidance to referrers on appropriateness and urgency of testing. 
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In keeping with these requirements, in the prototype version of the eOrder tool, when 
clinical information is recorded, an algorithm based on Canadian stroke best practice 
recommendations returns a priority score (P1–3). If testing is not indicated based on the 
clinical information provided, the software generates a clinical decision support message 
to that effect. The eOrder tool will not prevent users from ordering a test if they wish to 
override the algorithm, but additional information will be required to submit. Following 
submission of the referral by ordering provider, the software interacts with the Vascular 
Lab’s scheduling interface and immediately returns an appointment within a timeframe 
appropriate to the level of risk. Screenshots of the eOrder tool (in development) are 
included in Appendix A.
As shown in Appendix A (page 85), at the Vascular Lab incoming referrals are 
displayed in a digital list according to priority level. Vascular Lab staff can manually 
interrogate each referral for additional information, and/or manually override the 
automatically booked appointment to provide the necessary flexibility at the lab to 
adjust the schedule, if necessary. The system can also be configured to send an alert 
when referrals queue beyond available appointments. In this way, visual monitoring of 
demand vs. capacity is possible, and real-time adjustments can be made by Vascular 
Lab staff to ensure highest priority patients are seen first and fastest. It is anticipated 
that implementation of the eOrder software will contribute to improved efficiency and 
appropriateness of carotid testing. The capacity to utilize an algorithm to risk stratify 
incoming referrals and designate priority of testing, and to provide an immediate booking 
within 24 hours for P1 patients, makes the eOrder tool novel and highly attractive.
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5.6 Limitations and Delimitations
This work originated as part of a process improvement initiative within Eastern Health 
and evolved to include Memorial University of Newfoundland and Labrador, and the 
Newfoundland and Labrador Centre for Health Information. The analysis provides novel 
information specific to local carotid artery imaging, however a limitation of the work is 
reduced generalizability beyond St. Clare’s Vascular Lab setting. Carotid imaging takes 
place at DI departments elsewhere within Eastern Health and the province. While it is 
anticipated that similar clinical and process characteristics would be found, care should 
be taken in generalizing these results to all provincial sites. 
While every attempt was made to employ a consistent and thorough approach 
throughout the analysis, it must be acknowledged that Phase I information was collected 
retrospectively and was not subject to standard definitions and data capture processes. 
Though the dataset is large, and vascular technicians utilized a basic template to 
document each encounter, it is anticipated that lack of standardized data capture between 
testers may have contributed to variability and bias in the results. For example, some 
technicians may have copied the referral information verbatim, whereas others may have 
extracted further clinical details from the patient which may have resulted in a change in 
‘appropriateness.’
In entries where values were missing or defective, the entire case was eliminated. 
This constituted less than 50 cases in over 19,000 or less than 0.5%, but nonetheless, 
these cases are not represented in the analysis.
In Phase II, data collection was purposeful and took place in or near real-time. 
To reduce variability and support least bias within the process, a template was utilized 
employing standard definitions. Data capture techniques used formatted fields where 
possible, and/or dichotomous values. To further reduce variability, one individual, (CC) 
was responsible for data capture, where possible. In the case of time-to-access testing 
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data, the 2016 measurements were manually collected per test, by CC. The follow-up 
information for 2016 and 2017 was collected and provided to the writer by Eastern 
Health’s Vascular Program in aggregate form, as mean values. This made it impossible 
to repeat the time-to-event analysis that was conducted on the 2015 data and impacts the 
ability to generalize about sustainment of the changes. As a mean value for time-to-access 
testing can only include those who actually had a test, it is likely that the true access time 
in 2016/17 is underestimated. 
Due to the nature of the initiative, no attempts were made to introduce blinding 
or randomization into the process and study design did not enable comparison to a 
control group. Future evaluation following the implementation of the new eOrder 
software may rely upon this work to act as a control against which to evaluate the new 
electronic process.
During Phase III stakeholder consultations, efforts were made to include a 
representative sample of stakeholders and to accurately document and theme their 
responses. Two recorders were used and their original documentation was compared to 
ensure similar interpretation. Where possible, a summary of findings was provided to 
stakeholders for their review and approval after each session. Despite efforts to maintain 
objectivity during requirements-gathering sessions, the participation of those with 
specific experience may have influenced outcomes. For example, Vascular Lab staff were 
particularly vocal about patient delays due to booking appointments. In response to this, 
the functionality for the eOrder software to generate an appointment in real-time became 
a prime requirement. While it is possible that a particular stakeholder(s)’ views became 
more prominently positioned during the sessions, the final requirements define a process 
that is internally consistent with effective carotid artery imaging.
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CHAPTER 6 – CONCLUSION
The results show the annual volume of carotid artery U/S imaging at St. Clare’s Vascular 
Lab declined 2007–2015 and stabilized between 2015 and 2019. From 2015–2019 there 
was growth in the volume of carotid imaging carried out via CTA/MRA at Eastern Health 
sites external to the Vascular Lab. Characteristics of the population tested at the Vascular 
Lab, including age and risk factors, are consistent with a population at risk for stroke, 
however documentation of ‘reason for test’ and incidence of normal test findings suggest 
high incidence of inappropriate testing. The findings also suggest disparity in access to 
testing between males and females, and raises important questions about local recognition 
and reaction to high-risk symptoms in women, and management of women by the local 
health care system
Baseline sampling of incoming referrals demonstrated protracted wait times 
across all priority groups. Current processes for referring patients for carotid imaging at 
the Vascular Lab are paper-based and do not guarantee transmission of CTQ information 
necessary for accurate triage. Sampling revealed information deficiencies in incoming 
paper-based referrals consistently necessitating re-work, and contributing to delays for 
patients needing urgent access. In the current process, there is limited opportunity for 
efficient monitoring for quality assurance/quality improvement purposes.
Time-to-access testing and referral quality improved in association with 
enhancements to the paper requisition, improvements to the lab’s triage and scheduling 
processes, and knowledge translation initiatives customized to specific stakeholder 
groups. While improvements in referral quality, time-to-access, and process efficiency 
were observed, considerable manual effort was necessary to track wait times, queue size, 
and referral quality on an ongoing basis, and for sustainment of the improvements. It was 
noted that when attention to quality monitoring by individuals leading the Phase II QI 
initiative was withdrawn, there was a tendency for wait times and priority queues to creep 
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up. The objective findings and subjective experience suggest paper-based processing for 
multi-step, multi-stakeholder care is sub-optimal. A more efficient system enabling real-
time processing and visual management of supply/demand is recommended.
Learnings from phase I and II, as well as the findings of stakeholder consultations 
informed the design of an electronic ordering solution for carotid artery investigation. 
Key functionality for referrers includes the ability to complete referrals quickly, 
accurately, and without duplication; rapid and secure transmission of completed 
requests; and, immediate notification of risk (priority score) with appointment date/
time. Staff receiving completed referrals at the lab had identical requirements with the 
addition of legibility; mandatory fields with constrained formatting for CTQ clinical/
triage information; and, ability to link incoming referrals with referring provider using 
electronic identity authentication. 
The learnings of this research may be applied to future policy development, 
stakeholder education, and quality improvement in secondary stroke prevention. This 
work may form the baseline for a future evaluation of the design and implementation of 
the eOrder software.
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APPENDIX I – eORDER TOOL (IN DEVELOPMENT)
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Clicking on the Referrals tab at the top of the screen shows the patient’s referral history. 
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The eOrder is successfully submitted. The provider now clicks to book.
If this is not a suitable appointment, the user may select from a list of alternatives within the 
recommended guidelines – e.g. 24 hours for a P1.
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The Vascular Lab Clerk logs in and clicks their Referral Dashboard in the left menu to view queued exams.
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